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THE PRESIDENT’S REMEDY—WHAT THE
HYDROXYCHLOROQUINE STORY TEACHES US ABOUT
THE NEED TO LIMIT OFF-LABEL PRESCRIBING
POWERS
Jennifer S. Bard+

When the history of the first year of the United States Government’s response
to the COVID-19 virus is written, there is likely to be mention of the still
unexplained vehemence with which then president Donald J. Trump made use
of his access to social media to promote seldom used anti-malaria drug,
hydroxychloroquine, for both the prevention and treatment of COVID-19
despite the active growing opposition of most of the world’s scientists, including
his own government scientists.
While the use of drugs developed and approved by the FDA for different
purposes to combat new diseases, off-label prescribing, is legal in the United
States, the intense promotion of two drugs, hydroxychloroquine and ivermectin,
cast a light on what has always been a gap in the law between the federal
government’s power to approve drugs and the states’ power over the practice of
medicine. In particular, former President Trump’s advocacy over twitter and in
public appearances of hydroxychloroquine even after it had been found
ineffective by the FDA and the efforts of families throughout the country to
demand ivermectin, also found by the FDA to be ineffective, be administered to
their loved ones being treated for COVID-19 in ICU units highlights the need to
address this unsatisfactory compromise. Recent arguments that restricting drug
companies from promoting their products off-label are in violation of the first
amendment do not take into account social media fueled campaigns that
effectively strip FDA of all ability to protect consumers from ineffective and
perhaps unsafe drugs so long as it has ever approved them for any reason.
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INTRODUCTION
The COVID-19 pandemic has caused millions of deaths around the world and
challenged the medical and scientific community to develop safe and effective
methods of preventing and treating this new disease. The speed with which they
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have met this challenge is exceptional. But equally exceptional are the efforts
of physicians and health care workers who, starting in December 2019, had to
act immediately to take care of the first thousands, then millions of people who
began to fill hospitals. They had no other choice than to repurpose whatever
available medications might plausibly stop the virus’ reproduction. In the
United States, this experimentation was facilitated by the compromise struck
between the federal government, which exercises power over the approval of
drugs, and the practice of medicine.
When the history of the first year of the United States Government’s response
to the COVID-19 virus is written, there is likely to be mention of the still
unexplained vehemence with which then-president Donald J. Trump made use
of his access to social media to promote seldom-used anti-malaria drug,
hydroxychloroquine, for both the prevention and treatment of COVID-19
despite the active growing opposition of most of the world’s scientists, including
his own government scientists.1 He did so in a context where there was no safe
and effective treatment so that doctors around the world had to use the drugs at
hand while awaiting the development of ones fit for this purpose.2 While the
use of drugs developed and approved for different purposes to combat new
diseases is legal in the United States, President Trump’s advocacy provides an
opportunity for a closer look at the larger phenomena of “off-label” prescribing,
which represents a compromise between the U.S. Food and Drug
Administration’s (FDA) statutory authority to preauthorize new drugs and the
individual states’ plenary power recognized by the 10th Amendment to regulate
the practice of medicine within their borders.3 Within the context of this
compromise, the practice of repurposing drugs already approved by the FDA is
called using them “off-label” because the FDA’s statutory authority to
preauthorize drugs is structured in terms of prohibiting their sale without an FDA
approved “label.”4 As a result, any state licensed health care provider has the
1. See infra for a more detailed timeline of statements made by federal government
employees following specific endorsements by President Trump, such as this statement of Stephen
Hahn, then commissioner of the FDA in late July after President Trump doubled down on his
support for the drug in spite of medical evidence questioning its efficacy as a treatment for COVID19 and raising concerns over possible side effects. “We had data that when this drug was combined
with others, there was some risk associated with that. But the question you’re asking me is a
decision between a doctor and a patient.” Tal Axelrod, FDA Chief: Hydroxychloroquine Is a
Decision Between Doctor and Patient, THE HILL (July 30, 2020, 8:25 AM),
https://thehill.com/policy/healthcare/509733-fda-chief-hydroxychloroquine-use-a-decisionbetween-doctor-and-patient.
2. Joseph M. Geskey, Off-Label Prescribing in the Era of COVID-19, MED. ECON. (Apr. 14,
2020), https://www.medicaleconomics.com/med-ec-blog/label-prescribing-era-covid-19.
3. Amirahmad Shojaei & Pooneh Salari, COVID-19 and Off Label Use of Drugs: An Ethical
Viewpoint, 28 DARU J. PHARM. SCIS. 789, 789 (2020) (“There is no specific effective treatment
and optimized supportive care is indicated for the patients.”).
4. For a concise and helpful overview of the current regulatory scene and the legal debate
surrounding it, see Elizabeth Richardson, Off-Label Drug Promotion, HEALTH AFFS. (June 30,
2016), https://www.healthaffairs.org/do/10.1377/hpb20160630.920075/full/. For more information
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freedom to treat any patient for any condition with any FDA approved drug
regardless of the purpose for which the drug was originally authorized.5
The Article proceeds as follows: Part I tells the story of President Trump’s
promotion of hydroxychloroquine and the effect it had on sales and use of the
product. Part II outlines the legal framework of off-label prescribing, Part III
looks at criticisms of and justifications for off label prescribing, Part IV looks at
how the patient safety issues inherent in off-label prescribing have been
obscured by concerns about the First Amendment rights of pharmaceutical
companies to promote their product, and Part V concludes by proposing some
solutions justified by likely continued use of off-label products to treat COVID19.
I. THE TALE OF PRESIDENT DONALD J. TRUMP’S PROMOTION OF
HYDROXYCHLOROQUINE: SETTING THE SCENE
Along with the sickness, death, and economic disaster that the novel COVID19 virus has brought to the world has been the unprecedented spectacle of a
President of the United States taking on the role of spokesman for two little-used
anti-malaria drugs, hydrochloroquine, marketed under the name Plaquenil, and
chloroquine—collectively referred to as hydroxychloroquine—that are among
the many medications being tried to combat a deadly new virus for which there
was no FDA approved treatment or vaccine.6
on what the FDA requires as part of a drug label, see Prescription Drug Labeling Resources, U.S.
FOOD & DRUG ADMIN. (Oct. 7, 2021), https://www.fda.gov/drugs/laws-acts-andrules/prescription-drug-labeling-resources.
5. Elizabeth Richardson, Off-Label Drug Promotion, HEALTH AFFS. (June 30, 2016),
https://www.healthaffairs.org/do/10.1377/hpb20160630.920075/full/.
6. COVID Data Tracker: United States at a Glance, CTRS. FOR DISEASE CONTROL &
PREVENTION, https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html (last
visited July 26, 2020); the excess deaths count gives a more accurate death count attributable to
COVID-19 at any point in time. See Excess Deaths Associated with COVID-19, CTRS. FOR
DISEASE CONTROL & PREVENTION, https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_
deaths.htm (last visited July 8, 2020); COVID-19’s Historic Impact, in the U.S. and Abroad, JOHN
HOPKINS UNIV. (Apr. 16, 2020), https://hub.jhu.edu/2020/04/16/coronavirus-impact-on-europeanamerican-economies/; About COVID-19, WASH. UNIV. IN ST. LOUIS, https://emergency.wustl.edu/
coronavirus-disease-covid-19/covid-19-faqs/about-covid 19/#:~:text=COVID%2D19%20is%20a,
to%20more%20serious%20diseases (last visited May 28, 2020). Some of the mosquitos which
carry Malaria have become resistant to its active ingredient chloroquine. See Drug Resistance in
the Malaria-Endemic World, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/malaria/malaria_worldwide/reduction/drug_resist (last visited July 1, 2020).
Although the President frequently capitalizes it, “hydroxychloroquine sulfate” is actually the
generic name for the drug manufactured by Sanofi as Plaquenil. See SANOFI-AVENTIS CANADA
INC., PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION: PLAQUENIL
(2021), http://products.sanofi.ca/en/plaquenil.pdf (“PLAQUENIL (hydroxychloroquine sulfate
tablets) belongs to the 4-aminoquinoline class. PLAQUENIL has been beneficial for patients with
rheumatoid arthritis and lupus erythematosus, especially chronic discoid lupus. The exact mode of
action in controlling these diseases is unknown. The action of this compound against malarial
parasites is similar to that of chloroquine phosphate.”); see Sanjai Sinha, Hydroxychloroquine,
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A. Documenting the Promotion During President Trump’s Term in Office
President Trump’s first public mention of the drug was in a tweet dated March
21, 2020, stating “HYDROXYCHLOROQUINE & AZITHROMYCIN, taken
together, have a real chance to be one of the biggest game changers in the history
of medicine.7 The FDA has moved mountains-Thank You!”8 The “mountains”
he referred to were the issuing of an “emergency use authorization”9 (“EUA”)
that allowed the drug’s addition to the national stockpile and limited approval
for its use in hospitalized patients.10 The Trump Twitter Archive notes three
different tweets mentioning hydroxychloroquine on March 22–23, 2020, two of
which are retweets of the result of a French study.11
DRUGS.COM
(July
2,
2020),
https://www.drugs.com/hydroxychloroquine.html
(“Hydroxychloroquine is a quinoline medicine used to treat or prevent malaria, a disease caused by
parasites that enter the body through the bite of a mosquito. Malaria is common in areas such as
Africa, South America, and Southern Asia. This medicine is not effective against all strains of
malaria. Hydroxychloroquine is not effective against all strains of malaria, or against malaria in
areas where the infection has been resistant to a similar drug called chloroquine.
Hydroxychloroquine is also used to treat symptoms of rheumatoid arthritis and discoid or systemic
lupus erythematosus.”). See also SANOFI-AVENTIS CANADA INC., PRODUCT MONOGRAPH
INCLUDING
PATIENT
MEDICATION
INFORMATION:
PLAQUENIL
4
(2021),
http://products.sanofi.ca/en/plaquenil.pdf; Joseph M. Geskey, Off-Label Prescribing in the Era of
COVID-19, MED. ECON. (Apr. 14, 2020), https://www.medicaleconomics.com/view/labelprescribing-era-covid-19 (“Despite no evidence-based literature supporting a standard-of-care for
coronavirus infections, many providers are prophylactically prescribing medications like
Hydroxychloroquine and Azithromycin in the hope that it will arrest the virus from causing a
‘cytokine storm.’”); see also Steve Almond, Why America Can’t Stop COVID-19, WBUR (May
13, 2020), https://www.wbur.org/cognoscenti/2020/05/13/coronavirus-donald-trump-gop-stevealmond.
7. Tamara Keith & Malaka Gharib, A Timeline of Coronavirus Comments From President
Trump
and
WHO,
NPR
(Apr.
15,
2020,
5:33
PM),
https://www.npr.org/sections/goatsandsoda/2020/04/15/835011346/a-timeline-of-coronaviruscomments-from-president-trump-and-who; Donald J. Trump (@realDonaldTrump), TRUMP
TWITTER ARCHIVE V2 (Mar. 21, 2020, 10:13 AM), https://www.thetrumparchive.com/.
8. Donald J. Trump (@realdonaldtrump), TRUMP TWITTER ARCHIVE V2 (Mar. 21, 2020,
10:13 AM), https://www.thetrumparchive.com/; Coronavirus (COVID-19) Update: Daily Roundup
March 30, 2020, U.S. FOOD & DRUG ADMIN. (Mar. 30, 2020), https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-daily-roundup-march-30-2020.
9. Letter from Denise M. Hinton, Chief Scientist, FDA, to Rick Bright, Dir., Biomedical
Advanced Rsch. and Dev. Auth., U.S. Dep’t Health and Hum. Servs. (Mar. 28, 2020),
https://www.fda.gov/media/136534/download (last visited July 21, 2020) (currently marked
“Revoked”).
10. Jennifer S. Bard, Human Subjects Research in Emergencies: The Texas Nursing Home
‘Study’ (Part II), HARV. L. SCH.: BILL OF HEALTH (Apr. 27, 2020),
https://blog.petrieflom.law.harvard.edu/2020/04/27/human-subjects-researchhydroxychloroquine-texas-covid19/#more-28705.
11. Donald J. Trump (@realdonaldtrump), TRUMP TWITTER ARCHIVE V2 (Mar. 21, 2020,
10:13 AM), https://www.thetrumparchive.com/; Donald J. Trump (@realdonaldtrump), TRUMP
TWITTER ARCHIVE V2 (Mar. 21, 2020, 12:16 PM), https://www.thetrumparchive.com/; Donald J.
Trump (@realdonaldtrump), TRUMP TWITTER ARCHIVE V2 (Mar. 22, 2020, 12:15 AM),
https://www.thetrumparchive.com/; Kacper Niburski & Oskar Niburski, Impact of Trump’s
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At that time, no drug, including hydroxychloroquine, had FDA approval for
sale in the United States for the treatment of COVID-19. The EUA had the
effect of converting hydroxychloroquine from unapproved for COVID-19 to
approved in the specific circumstances detailed in the EUA. Not only was the
drug approved for emergency use, it was added to the Strategic National
Stockpile (“SNS”), a federally managed program to maintain medicines,
medical devices, like ventilators, and medical supplies in case of national
emergency.12 The significance of adding hydroxychloroquine to the stockpile
was so that “[t]he U.S. Department of Health and Human Services
(HHS) . . . [could] accept[] . . . 30 million doses” donated by several of the
companies which manufactured drugs containing hydroxychloroquine sulfate.13
For about a month, much to the concern of physicians treating COVID-19
patients, Americans were treated to the extraordinary sight of the President of
the United States speaking to them in live news conferences and then from the
White House to urge them to ask to be prescribed a specific drug.14 At a March
23, 2020, press briefing, the President announced that he was “a big fan” of the
drug’s promise against COVID-19 even as he acknowledged that it needed to be
tested first.15 On June 3, 2020, President Trump announced that he, himself, had
taken a two week preventive course of hydroxychloroquine.16

Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational
Study, 22 J. MED. INTERNET RSCH. (2020), https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC7685699/?.
12. Public Health Emergency: Strategic National Stockpile, U.S. DEP’T OF HEALTH AND
HUM. SERVS. (last reviewed Aug. 9, 2021), https://www.phe.gov/about/sns/Pages/default.aspx.
13. In particular, the drugs were “donated by Sandoz, the Novartis generics and biosimilars
division, and one million doses of Resochin (medical grade chloroquine phosphate) donated by
Bayer Pharmaceuticals . . . .” HHS Accepts Donations of Medicine to Strategic National Stockpile
as Possible Treatments for COVID-19 Patients, U.S. DEP’T OF HEALTH AND HUM. SERVS. (Mar.
29, 2020), https://www.hhs.gov/about/news/2020/03/29/hhs-accepts-donations-of-medicine-tostrategic-national-stockpile-as-possible-treatments-for-covid-19-patients.html.
14. Peter Baker et al., Trump’s Aggressive Advocacy of Malaria Drug for Treating
Coronavirus Divides Medical Community, N.Y. TIMES (Apr. 6, 2020), https://www.nytimes.com/
2020/04/06/us/politics/coronavirus-trump-malaria-drug.html.; Philip Bump, Trump’s Promotion of
Hydroxychloroquine Is Almost Certainly About Politics, Not Profits, WASH. POST (Aug. 7, 2020),
https://www.washingtonpost.com/politics/2020/04/07/trumps-promotion-hydroxychloroquine-isalmost-certainly-about-politics-not-profits/.
15. Tamara Keith & Malaka Gharib, A Timeline of Coronavirus Comments From President
Trump and WHO, NPR (Apr. 15, 2020, 5:33 PM), https://www.npr.org/sections/
goatsandsoda/2020/04/15/835011346/a-timeline-of-coronavirus-comments-from-president-trump
-and-who; Donald J. Trump (@realDonaldTrump), TRUMP TWITTER ARCHIVE V2 (Mar. 21, 2020,
10:13:08–09 AM), https://www.thetrumparchive.com/; Libby Cathey, Timeline: Tracking Trump
Alongside Scientific Developments on Hydroxychloroquine, ABC NEWS (Aug. 8, 2020, 8:12 AM),
https://abcnews.go.com/Health/timeline-tracking-trump-alongside-scientific-developmentshydroxychloroquine/story?id=72170553.
16. Katie Rogers & Lawrence K. Altman, Trump ‘Remains Healthy’ After Taking
Hydroxychloroquine, His Doctor Says, N. Y. TIMES (June 3, 2020), https://www.nytimes.com/
2020/06/03/us/politics/trump-physical-hydroxychloroquine.html.
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The President’s unusual advocacy for a specific drug attracted the attention of
the media, which soon found many sources tempering enthusiasm by pointing
to both the lack of evidence that hydroxychloroquine was effective in
combatting COVID-19 and, more seriously, that there were significant safety
concerns.17 Not only was the President claiming hydroxychloroquine was a cure
for COVID-19, he also touted it as a preventative, even though no clinical trials
had found any such evidence.18 In late April 2020, the announcement by a
director of a nursing home in Texas that he had obtained hydroxychloroquine
through a political connection and administered it as “an experiment” to 39
patients sick with COVID-19 was met with serious concern from ethicists,
scientists, and regulators.19 As if the story was not interesting enough, on April
22, 2020, the New York Times reported that a former HHS official was going to
testify as a whistleblower to Congress based on retaliation against him for
opposing the addition of hydroxychloroquine to the national stockpile.20 Dr.
Rick Bright testified that he was pressured to direct money toward
hydroxychloroquine, one of several “potentially dangerous drugs promoted by
those with political connections.”21 Responding directly to Dr. Bright’s
testimony in a tweet on May 18, 2020 which was “liked” by 82.4K Twitter users,
retweeted by 26.6K, and commented on by 11.8K, President Trump said “The
so-called HHS Whistleblower was against HYDROXYCHLOROQUINE. Then
why did he make, and sign, an emergency use authorization?”22 Perhaps to
bolster his earlier advocacy and negate Dr. Bright’s testimony, on May 18, 2020
the President announced to a briefing room of reporters while on live television
17. Oliver Milman, Trump Touts Hydroxychloroquine as a Cure for Covid-19. Don’t Believe
the Hype, THE GUARDIAN (Apr. 6, 2020, 2:33 PM), https://www.theguardian.com/
science/2020/apr/06/coronavirus-cure-fact-check-hydroxychloroquine-trump (reviewing the
President’s advocacy for the drug and noting that “Trump has been repeatedly contradicted by
public health experts including his own top infectious diseases adviser, Dr Anthony Fauci, who has
warned that there is only ‘anecdotal evidence’ that the drugs could be helpful”).
18. Robin E. Ferner & Jeffrey K. Aronson, Hydroxychloroquine for COVID-19: What Do The
Clinical Trials Tell Us?, CTR. FOR EVIDENCE BASED MED. (Apr. 14, 2020),
https://www.cebm.net/covid-19/hydroxychloroquine-for-covid-19-what-do-the-clinical-trials-tellus/.
19. For an account of the events at the Texas Nursing Home based on information available
in April 2020, see Jennifer S. Bard, Human Subjects Research in Emergencies: The Texas Nursing
Home “Study” (Part II), HARV. L. SCH.: BILL OF HEALTH (Apr. 27, 2020),
https://blog.petrieflom.law.harvard.edu/2020/04/27/human-subjects-research-hydroxychloroquine
-texas-covid19/#more-28705.
20. Michael D. Shear & Maggie Haberman, Health Dept. Official Says Doubts on
Hydroxychloroquine Led to His Ouster, N.Y. TIMES (Aug. 9, 2021), https://www.nytimes.com/
2020/04/22/us/politics/rick-bright-trump-hydroxychloroquine-coronavirus.html; see also Laurel
Wamsley, Rick Bright, Former Top Vaccine Scientist, Files Whistleblower Complaint, NPR (May
5,
2020,
7:03
PM),
https://www.npr.org/sections/coronavirus-live-updates/2020
/05/05/850960344/rick-bright-former-top-vaccine-scientist-files-whistleblower-complaint.
21. Id.
22. Donald J. Trump (@realDonaldTrump), TRUMP TWITTER ARCHIVE V2 (May 18, 2020,
10:44 AM), https://twitter.com/realdonaldtrump/status/1262393595560067073.
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that he, himself was taking the drug as a preventative.23 This triggered a press
request for a statement from the president’s physician which, when it appeared,
did not state directly that the President had ingested the drug so much as it stated
the President’s medical team “concluded the potential benefits from treatment
outweighed the relative risks.”24 On May 18, 2020 in which he responded to an
article criticizing his taking the drug by Neil Cavuto, the President retweeted,
“CAVUTO IS AN IDIOT. THIS DRUG DOES NOT KILL PEOPLE.”25
On May 24, the President announced in an interview with Sharyl Attkisson
that he was no longer taking the drug.26 On May 25, the World Health
Organization announced that it was suspending its global trial of
hydroxychloroquine because of “safety” concerns.27
But as quickly as hydroxychloroquine rose to prominence, its fall from favor
was just as fast. On June 15, 2020, the FDA revoked the EAU and removed it
from the national stockpile.28
Information about hydroxychloroquine continues to develop. A study in the
prestigious British journal, the Lancet, which reported that hydroxychloroquine
was linked to increased risk of death in COVID-19 patients, was retracted.29 Yet
23. Anne Gearan et al., Trump Says He is Taking Hydroxychloroquine to Protect Against
Coronavirus,
Dismissing
Safety
Concerns,
WASH. POST
(May
18,
2020),
https://www.washingtonpost.com/politics/trump-says-he-is-taking-hydroxychloroquine-toprotect-against-coronavirus-dismissing-safety-concerns/2020/05/18/7b8c928a-9946-11ea-ac723841fcc9b35f_story.html.
24. Trump’s Physician Releases Letter on President Taking Hydroxychloroquine, CNN (May
18,
2020,
8:47
PM),
https://www.cnn.com/2020/05/18/politics/trump-physician-onhydroxychloroquine/index.html.
25. Donald J. Trump (@realdonaldtrump), TRUMP TWITTER ARCHIVE (May 18, 2020),
http://trumptwitterarchive.com/archive.
26. Full Measure: May 24, 2020 - Interview with the President, FULL MEASURE (May 24,
2020), http://fullmeasure.news/news/full-episodes/full-measure-may-24-2020-interview-with-thepresident (“Sharyl: Many people are taking the government guidance on the anti-malaria drug,
hydroxychloroquine to basically ward them off of using it and trying it. On the other hand, there
are current experiments going on by National Institutes of Health and academic institutions,
including for preventive uses possibly, you’re finishing your two-week course of
hydroxychloroquine, correct? President Trump: Finished, just finished, yeah.”).
27. Coronavirus: WHO Halts Trials of Hydroxychloroquine Over Safety Fears, BBC NEWS
(May 25, 2020), https://www.bbc.com/news/health-52799120.
28. EUA Hydroxychloroquine Sulfate Health Care Provider Fact Sheet, U.S. FOOD & DRUG
ADMIN. (posted Apr. 27, 2020, revoked June 15, 2020), https://www.fda.gov/media/
136537/download. For contemporary retrospective of the time between the FDA’s issuance and
withdrawal of the EAU, see Sheryl Gay Stolberg, A Mad Scramble to Stock Millions of Malaria
Pills, Likely for Nothing, N.Y. TIMES (June 16, 2020), https://www.nytimes.com/
2020/06/16/us/politics/trump-hydroxychloroquine-coronavirus.html. Coronavirus: WHO Halts
Trials of Hydroxychloroquine Over Safety Fears, BBC NEWS, (May 25, 2020),
https://www.bbc.com/news/health-52799120 (discussing the suspension of trials of
hydroxychloroquine in several countries).
29. Marisa Fernandez, Update: Study Linking Hydroxychloroquine to Increased Death is
Retracted, AXIOS (May 22, 2020), https://www.axios.com/hydroxychloroquine-coronavirusincrease-death-e530f64b-feb2-47bc-8d4b-6d98f79ed5cc.html.
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former FDA Commissioner Scott Gottlieb downplayed the significance of the
retraction stating that while the study might be flawed, “hydroxychloroquine
‘definitively’ does not work as a coronavirus treatment.”30 On July 6, President
Trump cited the Detroit study to complain that “HYDROXYCHLOROQUINE
cut the death rate in certain sick patients very significantly” but “The Dems
disparaged it for political reasons (me!). Disgraceful” and he concluded by
exhorting @US_FDA to “Act now” to reissue the emergency use
authorization.31 On July 10, The Washington Post reported that “White House
trade adviser Peter Navarro is leading a Trump administration effort to demand
the Food and Drug Administration reverse course and grant a second emergency
authorization for the antimalarial drug hydroxychloroquine . . . .”32 The
President’s advocacy continued throughout the summer of 2020.33 On July 28,
2020, more than a month after the FDA had revoked its EUA, he posted a video
of a group of doctors declaring that “hydroxychloroquine is a coronavirus ‘cure’
and that masks are unnecessary.”34 When confronted with statements by Dr.
Fauci on July 29 denouncing the group as “peddling coronavirus
disinformation,” the President reasserted his faith in hydroxychloroquine saying
that, “I happen to think it works in the early stages . . . .”35

30. Ursula Perano, Former FDA Head Scott Gottlieb: “We Can Definitively Say
Hydroxychloroquine Doesn’t Work”, AXIOS (July 29, 2020), https://www.axios.com/
hydroxychloroquine-coronavirus-scott-gottlieb-trump-a7b60575-91db-4239-8c8659b993c55358.html.
31. Donald J. Trump (@realdonaldtrump), TRUMP TWITTER ARCHIVE V2 (July 6, 2020,
10:46 PM), http://trumptwitterarchive.com/archive (last visited July 26, 2020); Aaron Blake,
Trump is Making it Harder and Harder to Escape Blame on the Coronavirus, WASH. POST (July
8, 2020), https://www.washingtonpost.com/politics/2020/07/08/trump-is-making-it-harder-harderescape-blame-coronavirus/.
32. “Navarro, armed with a new study that he says shows the drug’s effectiveness, is being
cheered on by President Trump, who has long touted the drug as a ‘game changer.’” See Laurie
McGinley & Josh Dawsey, Touting Criticized Study, White House Presses FDA to Authorize
Hydroxychloroquine – Again, WASH. POST (July 10, 2020), https://www.washingtonpost.com/
health/2020/07/10/peter-navarro-hydroxychloroquine-coronavirus/.
33. Jason Easley, Trump Self-Destructs and Attacks CNN and MSNBC While Defending
Hydroxychloroquine, POLITICS USA (July 29, 2020), https://www.politicususa.com/2020/07/29/
trump-cnn-msnbc-hydroxychloroquine.html.
34. Justin Baragona, Dr. Fauci Rails Against COVID Disinformation Video Featuring Demon
Sperm Doctor, DAILY BEAST (July 29, 2020, 2:53 PM), https://www.thedailybeast.com/dr-faucirails-against-covid-disinformation-video-featuring-demon-sperm-doctor; Lev Facher et al., FDA
revokes emergency use ruling for hydroxychloroquine, the drug touted by Trump as a Covid-19
therapy, STAT (2020), https://www.statnews.com/2020/06/15/fda-revokes-hydroxychloroquine/
(last visited Apr. 8, 2022).
35. Id.; Quint Forgey & Caitlin Oprysko, “I Happen to Think it Works”: Trump Doubles
Down on Hydroxychloroquine, POLITICO (July 28, 2020, 7:12 PM), https://www.politico.com/
news/2020/07/28/fauci-trump-ineffective-coronavirus-treatment-383809.
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B. Immediate Consequences of Presidential Advocacy
President Trump’s endorsement of hydroxychloroquine influenced many to
seek it out.36 An article published on March 25, 2020 quoted executive director
of the Massachusetts Independent Pharmacists Association, Todd Brown, who
told a reporter that “[o]ur members are definitely seeing more demand for this
medication and possibly some people trying to hoard the medication.”37 Brown
is further attributed as saying that “it appears the hoarders included doctors and
dentists who are writing prescriptions for themselves or family members.”38 His
perception of increased prescriptions was supported by the executive director of
the National Association of Boards of Pharmacy, who said that “[b]ased on
reports we see from the states, pharmacists have a fairly good idea that what
they’re seeing is prescribers prescribing for themselves and their families and
stockpiling these medications rather than prescribing for patients.”39 She further
noted that six states had already “taken steps to limit inappropriate prescriptions
for hydroxychloroquine and preserve supplies for patients who take the medicine
as approved.”40
Another, tragic sign that the President’s message was effective came from the
wife of a man in California who died because they took, on the President’s
advice, what they believed to be a similar sounding component used to clean
fish tanks which would work to prevent COVID-19.41
On April 14, 2020, Dr. Joseph M. Geskey wrote a column in Medical
Economics that cited President Trump’s tweets and sought to advise physicians
of “potential pitfalls” that they “need to know about” in prescribing off-label.
He empathized, however, with their “understandable bias toward action” and
their adoption of the slogan, “Don’t just stand there. Do something.”42

36. See Martha Bebinger, Why Hoarding of Hydroxychloroquine Needs to Stop, WBUR
(Mar. 25, 2020), https://khn.org/news/why-hoarding-of-hydroxychloroquine-needs-to-stop/
(“Pharmacists are seeing an increase in requests and prescriptions for them in instances where it’s
not clear why the patient needs it at this time.”).
37. Id.
38. Id.
39. Id.
40. Id.
41. Scott Neuman, Man Dies, Woman Hospitalized After Taking Form Of Chloroquine to
Prevent COVID-19, NPR (Mar. 24, 2020, 4:20 AM), https://www.npr.org/sections/coronaviruslive-updates/2020/03/24/820512107/man-dies-woman-hospitalized-after-taking-form-ofchloroquine-to-prevent-covid-19; see also Erika Edwards & Vaughn Hillyard, Man Dies After
Taking Chloroquine in an Attempt to Prevent Coronavirus, NBC NEWS (Mar. 23, 2020, 5:53 PM),
https://www.nbcnews.com/health/health-news/man-dies-after-ingesting-chloroquine-attemptprevent-coronavirus-n1167166 (“The man’s wife told NBC News she’d watched televised
briefings during which President Trump talked about the potential benefits of chloroquine.”).
42. Joseph M. Geskey, Off-Label Prescribing in the Era of COVID-19, MED. ECONS. (Apr.
14, 2020), https://www.medicaleconomics.com/view/label-prescribing-era-covid-19.
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Soon, evidence began to emerge of a rise in prescriptions sparking a run on
the drug.43 People seeking their regular prescriptions for conditions such as
Lupus became concerned.44 Further evidence emerged that many of the
prescriptions were written by doctors outside of those who could be expected to
treat COVID-19 patients, such as urologists, dermatologists, and podiatrists.45
More to the point, evidence emerged that they were writing prescriptions for
themselves and their friends.46 Predictably, supplies of hydroxychloroquine ran
short and people who depended on it had difficulty filling their prescriptions.47
The shortage became so concerning that the American Medical Association
(AMA) felt it necessary to call “for a stop to any inappropriate prescribing and
ordering of medications, including chloroquine or hydroxychloroquine, and
appealing to physicians and all health care professionals to follow the highest
43. Ariana Eunjung Cha & Laurie McGinley, Antimalarial Drug Touted by President Trump
is Linked to Increased Risk of Death in Coronavirus Patients, Study Says, WASH. POST (May 22,
2020),
https://www.washingtonpost.com/health/2020/05/22/hydroxychloroquine-coronavirusstudy/.
44. Maya L. Harris, Some Patients Really Need the Drug That Trump Keeps Pushing, THE
ATLANTIC
(Apr.
12,
2020),
https://www.theatlantic.com/ideas/archive/2020/04/savehydroxychloroquine-people-like-me/609865/; FDA Recognizes Hydroxychloroquine and
Chloroquine
Shortages,
LUPUS
FOUND.
OF
AMER.
(Mar.
31,
2020),
https://www.lupus.org/news/fda-recognizes-hydroxychloroquine-and-chloroquine-shortages
(“The agency is working with manufacturers to assess their supplies and is actively evaluating
market demand for patients dependent on hydroxychloroquine and chloroquine for treatment of
malaria, lupus and rheumatoid arthritis. All manufacturers are ramping up production, and the
agency’s webpage displays current availability.”).
45. Further research will tell us more about what was actually happening. The fact that there
is a requirement to indicate on a prescription the condition of the patient for whom it is written
means that it is difficult to know if these prescriptions were for patients showing different
manifestations of COVID-19. See Ellen Gabler & Michael H. Keller, Prescriptions Surged as
Trump Praised Drugs in Coronavirus Fight, N.Y. TIMES (Oct. 22, 2020), https://www.nytimes.com
/2020/04/25/us/coronavirus-trump-chloroquine-hydroxychloroquine.html; see also Jinoos
Yazdany & Alfred H.J. Kim, Use of Hydroxychloroquine and Chloroquine During the COVID-19
Pandemic: What Every Clinician Should Know, ANNALS OF INTERNAL MED. (June 2, 2020),
https://www.acpjournals.org/doi/10.7326/M20-1334 (“Hoarding by health professionals for
themselves and their friends or family is already occurring, but state governments and pharmacy
boards have started to institute strict utilization policies to prevent further HCQ overutilization.”).
46. Doctors are Prescribing Drug that May Help Treat Coronavirus for Family and Friends:
“Unethical and Selfish,” CBS NEWS (Mar. 26, 2020, 8:43 AM), https://www.cbsnews.com/news/
coronavirus-treatment-drug-hydroxychloroquine-doctor-prescription-family-friends/.
47. The shortage seems to be easing as of July 1, 2020. See EJ Dickson, Thanks to Trump,
There’s a Hydroxychloroquine Shortage for People Who Need It, ROLLING STONE (Apr. 6, 2020,
4:09 PM), https://www.rollingstone.com/culture/culture-news/hydroxychloroquine-trump-corona
virus-covid19-pandemic-miracle-drug-978994/; see also State Action on Hydroxychloroquine and
Chloroquine Access, LUPUS FOUND. OF AM. (last accessed July 30, 2020),
https://www.lupus.org/advocate/state-action-on-hydroxychloroquine-and-chloroquine-access;
Ken Alltucker, ‘Medication I can’t live without’: Lupus Patients Struggle to Get
Hydroxychloroquine, In Demand for COVID-19, USA TODAY (Apr. 19, 2020, 12:22 PM),
https://www.usatoday.com/story/news/health/2020/04/18/hydroxychloroquine-coronaviruscreates-shortage-lupus-drug/5129896002/.
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standards of professionalism and ethics.”48 Evidence of hoarding continues to
emerge.49
The President’s comments also affected clinical trials for other potential
treatments. In some cases, patients refused to forgo the option of receiving
hydroxychloroquine.50 More generally, so long as the FDA endorsed
hydroxychloroquine as a treatment, it was necessary to include it in comparative
studies of other potential treatments which may have had the effect of
magnifying even very modest effects.51 Even worse, it is necessary to continue
testing hydroxychloroquine, long after the findings that have caused many
countries to prematurely end trials.52 Finally, if that were not damage enough,
it may be necessary to conduct trials for new drugs comparing them to
hydroxychloroquine.53
Over time, the President’s advocacy of hydroxychloroquine in the face of
growing scientific evidence that it did not work became a proxy for supporting
President Trump against a “deep state” conspiracy mounted against him.54
C. Effect of Advocacy After President Trump Left Office
Neither President Trump’s loss of the election to Joe Biden nor ban from
Twitter has dampened the enthusiasm of those who supported him for the use of

48. Boards of Pharmacy and Other Actions Relating to COVID-19 Prescribing, AM. MED.
ASS’N (Apr. 27, 2020, 9:00 AM), https://www.ama-assn.org/system/files/2020-04/board-ofpharmacy-covid-19-prescribing.pdf; Joint Statement on Ordering, Prescribing or Dispensing
COVID-19 Medications, AM. MED. ASS’N (Apr. 17, 2020), https://www.ama-assn.org/deliveringcare/public-health/joint-statement-ordering-prescribing-or-dispensing-covid-19; Ellen Gabler,
States Say Some Doctors Stockpile Trial Coronavirus Drugs, for Themselves, N.Y. TIMES (Apr. 9,
2020), https://www.nytimes.com/2020/03/24/business/doctors-buying-coronavirus-drugs.html.
49. Jacquie Lee, Virus Drug Hoarding Prompts Calls for Accessible Data, Supplies,
BLOOMBERG L. (July 17, 2020, 5:26 AM), https://news.bloomberglaw.com/pharma-and-lifesciences/virus-drug-hoarding-prompts-calls-for-accessible-data-supplies.
50. Sara Talpos, Is Hydroxychloroquine Making COVID-19 Clinical Trials Harder?,
MEDSCAPE (Apr. 15, 2020), https://www.medscape.com/viewarticle/928719.
51. NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19,
NAT’L INSTS. HEALTH (May 14, 2020), https://www.nih.gov/news-events/news-releases/nihbegins-clinical-trial-hydroxychloroquine-azithromycin-treat-covid-19.
52. Marie McCullough, Hydroxychloroquine is the Most Disappointing, Disavowed Drug
that Researchers Keep Studying for COVID-19, MED. XPRESS (July 6, 2020),
https://medicalxpress.com/news/2020-07-hydroxychloroquine-disappointing-disavowed-drugcovid-.html.
53. Matthew Herper & Erin Riglin, Data Show Panic and Disorganization Dominate the
Study of Covid-19 Drugs, STAT (July 6, 2020), https://www.statnews.com/2020/07/06/data-showpanic-and-disorganization-dominate-the-study-of-covid-19-drugs/.
54. Hydroxychloroquine & The Hybrid War on Trump’s America, ONEWORLD PRESS (Apr.
7, 2020), http://oneworld.press/?module=articles&action=view&id=1393 (“It obviously can’t be
known for sure, but there are serious grounds for speculating that the topic of Hydroxychloroquine
has been politicized by Dr. Fauci and his ‘deep state’ partners as part of their Hybrid War on
Trump’s America.”).
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hydroxychloroquine for COVID-19.55 Indeed, some of those being investigated
for storming the U.S. Capitol on January 6, 2021 are prominent advocates for
hydroxychloroquine.56 This transformation into a political cause is most clearly
evidenced by a lawsuit brought against Congressman Adam Schiff alleging that
his letter to Facebook urging it to stop the spread of false medical information
violates the First Amendment rights of those who would therefore be deprived
of information.57
The vacuum created by the lack of any proven effective treatments for
COVID-19 has created an almost unprecedented opportunity for pharmaceutical
companies to expand the sale of their existing products. There are no legal
barriers to physicians who wish to experiment by prescribing drugs for
unapproved purposes. But the legal barriers that prevent pharmaceutical
companies from promoting off-label use has turned them into nothing more than
highly interested bystanders.58
The barriers to promoting off-label use of prescription drugs to fight COVID19 do not extend beyond those who benefit financially: the pharmaceutical
companies. Without the constraint of legal prohibitions or concerns over
maintaining a professional license, individuals who promote off-label use of
drugs find themselves in the position of unpaid spokespeople. A holding, no
matter how unlikely, that these freelance promoters have First Amendment
rights that obligate social media platforms to carry their message should ring
alarm bells as close to unbelievable good fortune.

55. See Rush and Trump Were Right About Hydroxychloroquine, RUSH LIMBAUGH SHOW
(Mar. 10, 2021), https://www.rushlimbaugh.com/daily/2021/03/10/rush-and-trump-were-rightabout-hydroxychloroquine/ (“You know, regarding hydroxychloroquine, Trump was right about
hydroxychloroquine, and I think the problem with it is, it’s so cheap. And Big Pharma must own
Biden (chuckles) and must own Fauci as well. We’ve been using it.”).
56. Zack Budryk, Doctor that Promoted False Hydroxychloroquine Claims Arrested in
Connection with Capitol Riot, THE HILL (Jan. 21, 2021, 10:37 AM), https://thehill.com/policy/
healthcare/535202-head-of-fringe-medical-group-who-met-with-pence-arrested-in-connectionwith (“Federal officials this weekend arrested the head of a fringe medical group that has promoted
false claims about vaccines and the antimalarial drug hydroxychloroquine in connection with the
deadly Jan. 6 riot at the U.S. Capitol.”); see also Amanda D’Ambrosio, Simone Gold Arrested for
Role in Capitol Insurrection, MEDPAGETODAY (Jan. 20, 2021), https://www.medpagetoday.com/
washington-watch/washington-watch/90778 (“Simone Gold, MD, JD, founder of the notorious
pro-hydroxychloroquine, anti-vaccine group America’s Frontline Doctors, was arrested Sunday for
participating in storming the U.S. Capitol earlier this month[.]”).
57. Complaint at 4, Ass’n of Am. Physicians & Surgeons v. Schiff, No. 1:20-cv-106, 2021
WL 354174 (D.D.C. Jan. 15, 2020), https://aapsonline.org/judicial/aaps-v-schiff-1-15-2020.pdf.
58. See infra Section III.
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Amidst the sickness,59 death,60 and economic disaster61 that the novel
COVID-19 virus62 has brought to the world had been the unprecedented
spectacle of the President of the United States taking on the role of spokesman
for two little used anti-malaria drugs,63 hydrochloroquine,64 marketed under the
name Plaquenil,65 and chloroquine (collectively referred to as
hydroxychloroquine) that were, at the beginning of the pandemic, among the
many medications being tried to combat a deadly new virus before there were
any approved treatments or vaccines.66 He did so against a background of a
59. COVID Data Tracker, CTRS. DISEASE CONTROL & PREVENTION, https://www.cdc.gov/
coronavirus/2019-ncov/cases-updates/cases-in-us.html (last accessed July 26, 2020).
60. The excess deaths count gives a more accurate death count attributable to COVID-19 at
any point in time. See Excess Deaths Associated with COVID-19, CTRS. FOR DISEASE CONTROL
& PREVENTION, https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm (last visited Jan.
23, 2021).
61. JOHNS HOPKINS UNIV., COVID-19’s Historic Economic Impact, in the U.S. and Abroad,
HUB at 2, 4 (Apr. 16, 2020), https://hub.jhu.edu/2020/04/16/coronavirus-impact-on-europeanamerican-economies/.
62. About COVID-19, WASH. UNIV. IN ST. LOUIS, https://emergency.wustl.edu/coronavirusdisease-covid-19/covid-19-faqs/about-covid19/#:~:text=COVID%2D19%20is%20a,to%20more%20serious%20diseases (accessed May 28,
2020).
63. Some of the mosquitos which carry Malaria have become resistant to its active ingredient
chloroquine. See Drug Resistance in the Malaria-Endemic World, CTRS. FOR DISEASE CONTROL
& PREVENTION, (July 23, 2018), https://www.cdc.gov/malaria/malaria_worldwide/reduction/
drug_resistance.html.
64. Although the President frequently capitalizes it, “hydroxychloroquine sulfate” is actually
the generic name for the drug manufactured by Sanofi as Plaquenil. See SANOFI-AVENTIS CANADA
INC., Product Monograph Including Patient Medication Information, at 4, 24 (Oct. 18, 2021),
http://products.sanofi.ca/en/plaquenil.pdf (“PLAQUENIL (hydroxychloroquine sulfate tablets)
belongs to the 4-aminoquinoline class. PLAQUENIL has been beneficial for patients with
rheumatoid arthritis and lupus erythematosus, especially chronic discoid lupus. The exact mode of
action in controlling these diseases is unknown. The action of this compound against malarial
parasites is similar to that of chloroquine phosphate.”); see ASHP, Hydroxychloroquine,
DRUGS.COM
(Nov.
29,
2021),
https://www.drugs.com/hydroxychloroquine.html
(“Hydroxychloroquine is a quinoline medicine used to treat or prevent malaria, a disease caused by
parasites that enter the body through the bite of a mosquito. Malaria is common in areas such as
Africa, South America, and Southern Asia. This medicine is not effective against all strains of
malaria. Hydroxychloroquine is not effective against all strains of malaria, or against malaria in
areas where the infection has been resistant to a similar drug called chloroquine.
Hydroxychloroquine is also used to treat symptoms of rheumatoid arthritis and discoid or systemic
lupus erythematosus.”).
65. See SANOFI-AVENTIS CANADA INC., Product Monograph Including Patient Medication
Information, at 4 (Oct. 18, 2021), http://products.sanofi.ca/en/plaquenil.pdf.
66. See Joseph M. Geskey, Off-Label Prescribing in the Era of COVID-19, MED. ECON. at 1
(Apr. 14, 2020), https://www.medicaleconomics.com/view/label-prescribing-era-covid-19
(“Despite no evidence-based literature supporting a standard-of-care for coronavirus infections,
many providers are prophylactically prescribing medications like Hydroxychloroquine and
Azithromycin in the hope that it will arrest the virus from causing a ‘cytokine storm.’”); see also
Steve Almond, Why America Can’t Stop COVID-19, WBUR (May 13, 2020),
https://www.wbur.org/cognoscenti/2020/05/13/coronavirus-donald-trump-gop-steve-almond. The
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global pandemic where every country was facing ever increasing numbers of
cases, hospitalizations, and deaths in an environment without the existence of a
single treatment option approved by any national regulatory or creditable
scientific entity. In the absence of anything that could prevent the disease or
mitigate its severity, doctors used drugs approved for other purposes or
populations that they hoped would interfere with the virus’ replication or at least
reduce the severity of its life-threatening symptoms. The search for effective
therapeutic treatments advanced in parallel with intense efforts to develop
vaccines.67 By December 2021, there were three FDA approved vaccines to
prevent COVID-19.68 That some month, the FDA issued an emergency use
authorization for Pfizer’s Paxlovid.69 Biomedical researchers are still
developing specific treatments.70 Many initially promising interventions, like
convalescent plasma, have been reluctantly abandoned because they make no
difference in death rates or disease progression.71
We may never know the exact reason for the President’s relentless advocacy,
which continued long after the FDA withdrew its EUA.72 It continued despite

FDA approved the first treatment for Covid-19, eklury (remdesivir), on October 22, 2020. FDA
Approves First Treatment for COVID-19, U.S. FOOD & DRUG ADMIN. (Oct. 22, 2020),
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.
The first vaccine received FDA approval on August 23, 2021. FDA Approves First COVID-19
Vaccine, U.S. FOOD & DRUG ADMIN. (Aug. 31, 2021), https://www.fda.gov/news-events/pressannouncements/fda-approves-first-covid-19-vaccine.
67. COVID-19 therapeutics: Challenges and directions for the future, PNAS,
https://www.pnas.org/doi/10.1073/pnas.2119893119 (last visited Apr. 8, 2022).
68. Office of the Commissioner, COVID-19 Vaccines, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid19/covid-19-vaccines (last visited Apr. 8, 2022).
69. Office of the Commissioner, Coronavirus (COVID-19) Update: FDA Authorizes First
Oral Antiviral for Treatment of COVID-19 (2021), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fdaauthorizes-first-oral-antiviral-treatment-covid-19 (last visited Apr. 8, 2022).
70. COVID-19 therapeutics: Challenges and directions for the future, supra note 67;
Christopher Curley, Fluvoxamine Effective as a COVID-19 Treatment, HEALTHLINE (2022),
https://www.healthline.com/health-news/fluvoxamine-found-to-be-effective-as-a-covid-19treatment-the-benefits-and-limitations (last visited Apr. 8, 2022).
71. Rita Rubin, Once Viewed as a Promising COVID-19 Treatment, Convalescent Plasma
Falls. Maia Anderson, 3 drugs that have failed to benefit COVID-19 patients in clinical trials,
BECKER’S HOSPITAL REVIEWS (Nov. 18, 2020), https://www.beckershospitalreview.com/
pharmacy/3-drugs-that-have-failed-to-benefit-covid-19-patients-in-clinical-trials.html. See also
Out of Favor, JAMA (Mar. 9, 2022), https://jamanetwork.com/journals/jama/fullarticle/2790074.
72. The FDA issued its EUA for hydroxychloroquine on March 20, 2020 and withdrew it on
June 15, 2020. See Elangovan Manivannan et al., The Rise and Fall of Chloroquine/
Hydroxychloroquine as Compassionate Therapy of COVID-19, 12 FRONT. PHARMACOL. 584940
(2021). Facher et al., supra note 34. See also Andre C. Kalil, Treating COVID-19–Off-Label Drug
Use, Compassionate Use, and Randomized Clinical Trials During Pandemics, 323 J. AM. MED.
ASS’N 1897−98 (2020).
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being contradicted directly by his chief science advisor, Dr. Anthony Fauci.73
The President himself frequently denied any personal financial interest in
launching what had become an orphan drug with few uses. Malarial mosquitos
have long been immune to its effects, but it was certainly of financial interest to
the companies authorized to sell it. Whatever his motive, the success of
President Trump’s advocacy for hydroxychloroquine became visible almost
immediately.
D. The Case of Ivermectin
While President Trump was advocating for the use hydroxychloroquine, many
of the same medical entities promoting that drug were also enthusiastic about
the off-label repurposing of another FDA approved drug, ivermectin.74 One of
the first mainstream media mentions of ivermectin came from testimony in front
of the U.S. Senate Homeland Security Committee in testimony from Dr. Pierre
Kory.75 Dr. Kory, a pulmonologist from Wisconsin, was “president of the Front
Line COVID-19 Critical Care Alliance (FLCCC), a group of physicians and
scientists who champion ivermectin, along with other drugs and vitamins with
dubious efficacy against COVID.”76 Since then, there has been a consistent
stream of reporting about the FLCCC as well as the British Ivermectin
Recommendation Development (BIRD) Group and America’s Frontline Doctors
(AFLDS) advocating for ivermectin’s use to prevent and treat COVID-19.77
73. Justin Baragona, Dr. Fauci Rails Against COVID Disinformation Video Featuring Demon
Sperm Doctor, DAILY BEAST (July 29, 2020, 2:53 PM), https://www.thedailybeast.com/dr-faucirails-against-covid-disinformation-video-featuring-demon-sperm-doctor.
74. Emma Goldberg, Demand Surges for Deworming Drug for Covid, Despite Scant
Evidence It Works, N.Y. TIMES (Aug. 30, 2021), https://www.nytimes.com/2021/08/30/health/
covid-ivermectin-prescriptions.html; Carl Zimmer, Ivermectin Does Not Reduce Risk of Covid
Hospitalization, Large Study Finds, N.Y. TIMES (Mar. 30, 2022), https://www.nytimes.com/2022/
03/30/health/covid-ivermectin-hospitalization.html?searchResultPosition=1; Christina Szalinski,
Fringe Doctors’ Groups Promote Ivermectin for COVID despite a Lack of Evidence, SCI. AM.
(Sept. 29, 2021), https://www.scientificamerican.com/article/fringe-doctors-groups-promoteivermectin-for-covid-despite-a-lack-of-evidence/.
75. Oscar Gonzalez, Ivermectin: Why Are There Lawsuits Over This Unproven Drug, CNET
(Oct. 6, 2021, 5:00 AM), https://www.cnet.com/health/medical/ivermectin-and-covid-19-why-arethere-lawsuit-over-this-unproven-drug/; Christina Szalinski, Fringe Doctors’ Groups Promote
Ivermectin for COVID despite a Lack of Evidence, SCI. AM. (Sept. 29, 2021),
https://www.scientificamerican.com/article/fringe-doctors-groups-promote-ivermectin-for-coviddespite-a-lack-of-evidence/#.
76. Christina Szalinski, Fringe Doctors’ Groups Promote Ivermectin for COVID despite a
Lack of Evidence, SCI. AM. (Sept. 29, 2021), https://www.scientificamerican.com/article/fringedoctors-groups-promote-ivermectin-for-covid-despite-a-lack-of-evidence/#.
77. BRITISH IVERMECTIN RECOMMENDATION DEVELOPMENT, https://bird-group.org/;
AMERICA’S FRONTLINE DOCTORS, https://americasfrontlinedoctors.org/. See Nick Robins-Early,
Ivermectin Frenzy: the Advocates, Anti-vaxxers and Telehealth Companies Driving Demand, THE
GUARDIAN (Sept. 13, 2021, 6:00 AM), https://www.theguardian.com/world/2021/sep/13/
ivermectin-treatment-covid-19-anti-vaxxers-advocates (describing the two organizations as being
part of “a cottage industry of advocacy groups, anti-vaccine activists and telehealth companies”).
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The consensus of the scientific community in the United States and abroad is
that ivermectin is not effective in either treating or preventing COVID.78 The
FDA has publicly and aggressively advocated against the use of ivermectin to
treat COVID-19, writing that “[t]here’s a lot of misinformation around, and you
may have heard that it’s okay to take large doses of ivermectin. It is not okay.”79
On August 26, 2021, the CDC released an emergency warning stating that,
“[d]uring the COVID-19 pandemic, ivermectin dispensing by retail pharmacies
has increased, as has use of veterinary formulations available over the counter
but not intended for human use.”80 Citing a study that there had been a “a 24fold increase” of ivermectin prescriptions “from the pre-pandemic baseline,” the
warning linked this increase to “a three-fold increase in the number of calls for
human exposures to ivermectin in January 2021” made to poison control centers
across the United States.81 In July 2021, calls to poison control centers about
ivermectin increased five-fold from baseline.82 In response, the FDA issued a
warning that:
Even the levels of Ivermectin for approved human uses can interact
with other medications, like blood-thinners. You can also overdose
on Ivermectin, which can cause nausea, vomiting, diarrhea,
hypotension (low blood pressure), allergic reactions (itching and
hives), dizziness, ataxia (problems with balance), seizures, coma and
even death.83
Other organizations issuing similar warnings include the American Pharmacists
Association, American Medical Association, Cleveland Clinic, and Mayo
Clinic.84
78. EMA Advises Against Ivermectin Use for Covid-19 Outside Clinical Trials, PHARM.
TECH. (Mar. 23, 2021), https://www.pharmaceutical-technology.com/news/ivermectin-antiparasite-use-covid-19/ (“EMA concluded that the currently available evidence is not enough to
support the ivermectin’s use for COVID-19 outside clinical trials.”); Ivermectin is a Nobel PrizeWinning Wonder Drug – but Not for COVID-19, THE CONVERSATION (Oct. 14, 2021, 8:15 AM),
http://theconversation.com/ivermectin-is-a-nobel-prize-winning-wonder-drug-but-not-for-covid19-168449.
79. Why You Should Not Use Ivermectin to Treat or Prevent COVID-10, U.S. FOOD & DRUG
ADMIN., https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectintreat-or-prevent-covid-19 (last accessed Feb. 16, 2022).
80. Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with
Use of Products Containing Ivermectin to Prevent or Treat COVID-19, CTRS. FOR DISEASE
CONTROL & PREVENTION: HEALTH ALERT NETWORK (Aug. 26, 2021, 11:40 AM),
https://emergency.cdc.gov/han/2021/han00449.asp.
81. Id.
82. Id.
83. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19, U.S. FOOD & DRUG
ADMIN., https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectintreat-or-prevent-covid-19 (last accessed Feb. 16, 2022).
84. Sara Berg, Why Ivermectin Should Not Be Used to Prevent or Treat COVID-19, AM. MED.
ASS’N (Sept. 2, 2021), https://www.ama-assn.org/delivering-care/public-health/why-ivermectinshould-not-be-used-prevent-or-treat-covid-19; Why You Shouldn’t Take Ivermectin for COVID-19,
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Ivermectin has long been associated with serious neurological side-effects in
some people when taken as an anti-parasitic.85 While the reason some people
suffered from these side-effects while others did not is still the subject of
scientific review, the idea of people who were not infected with parasites or who
were taking it at the larger doses prescribe for animals caused immediate concern
in the scientific community most familiar with its use. This included not just the
major global health regulators and national health authorities, but also the drug’s
own manufacturer, Merck.86
As use of ivermectin became more common, state health departments began
putting out statements, such as this one from Alabama, warning that “[t]he
agency has received multiple reports of patients who have required medical
support and have been hospitalized after taking high doses of ivermectin which
can be highly toxic in humans. Side effects occur, and drug interactions are
common.”87 Similar warnings have been issued by health departments in South
Carolina.88 Yet despite continued evidence that ivermectin is not effective in
CLEVELAND CLINIC (Aug. 30, 2021), https://health.clevelandclinic.org/why-you-shouldnt-takeanimal-ivermectin-for-covid-19/; Daniel C. DeSimone, M.D., COVID-19 drugs: Are there any that
work?, MAYO CLINIC (Feb. 19, 2022), https://www.mayoclinic.org/diseases-conditions/corona
virus/expert-answers/coronavirus-drugs/faq-20485627.
85. Rebecca E. Chandler, Serious Neurological Adverse Events After Ivermectin—Do They
Occur Beyond the Indication of Onchocerciasis?, 98 AM. J. TROP. MED. HYG. 382–88 (2018),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929173/ (“Examples of serious neurological
adverse events reported included such terms as unable to walk, consciousness disturbed or
depressed level of consciousness or loss of consciousness, seizure or convulsion, encephalopathy
or coma, and tremor.”); see also Duong Khanh Toan et al., Ivermectin Poisoning – Report of
Successful Management, 58 INDIAN PEDIATRICS 893 (2021), https://www.ncbi.nlm.nih.gov
/pmc/articles/PMC8464184/pdf/13312_2021_Article_2316.pdf (“[S]eizures may be the clinical
presentation in children with cardiac channelopathy. Red flags such as a family history of sudden
death, seizures associated with auditory triggers and recurrent seizures with a normal EEG should
raise suspicion and prompt referral to a pediatric cardiologist.”).
86. See, e.g., Nial Wheate, Andrew McLachlan & Slade Matthews, Thinking of Trying
Ivermectin for COVID? Here’s What Can Happen With This Controversial Drug, UNIV. OF
SYDNEY (Sept. 3, 2021), https://www.sydney.edu.au/news-opinion/news/2021/09/03/-thinking-oftrying-ivermectin-for-covid-heres-what-can-happen-w.html; see also Risks of Importing or
Prescribing Ivermectin for Prevention or Treatment of COVID-19, N.Z. MEDS. & MED. DEVICES
SAFETY AUTH. (Sept. 6, 2021), https://www.medsafe.govt.nz/safety/Alerts/ivermectincovid19.htm; Merck Statement on Ivermectin Use During the COVID-19 Pandemic, MERCK (Feb.
4, 2021, 11:45 AM), https://www.merck.com/news/merck-statement-on-ivermectin-use-duringthe-covid-19-pandemic/.
87. ADPH Warns About Dangers of Self-Medicating With Large Quantities of Ivermectin,
WBRC (Aug. 25, 2021, 4:32 PM), https://www.wbrc.com/2021/08/25/adph-warns-about-dangersself-medicating-with-large-quantities-ivermectin/.
88. See The Dangers of Using Hydroxychloroquine and Ivermectin for Preventing or Treating
COVID-19, S.C. DEP’T OF HEALTH AND ENV’T CONTROL, https://scdhec.gov/covid19/dangersusing-hydroxychloroquine-ivermectin-preventing-or-treating-covid-19 (“Do not swallow
ivermectin lotion or cream that is meant for use on the skin. Taking large doses or doses intended
for animals is dangerous and can result in overdose, causing serious harm including nausea,
vomiting, diarrhea, low blood pressure, dizziness, balance problems, seizures, coma, and even
death. Ivermectin can cause birth defects if taken early in pregnancy. Dosages intended for animals
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treating or preventing COVID, its use remains popular.89 Many states have
passed or are considering legislation to make it easier for residents to obtain
ivermectin.90 While it is impossible to know if this misplaced faith in ivermectin
as with hydroxychloroquine has prevented people from seeking effective
treatments or vaccines, there is considerable evidence that those predisposed to
be skeptical of vaccines were often strong advocates of both drugs.91
II. OUTLINING THE LEGAL FRAMEWORK OF OFF-LABEL PRESCRIBING
A. Constitutional Basis of the Federal and State Shared Regulation of
Prescription Drugs
The current scheme of federal regulation over drugs is based on a 1906 law92
that exercised the power granted to Congress under the Commerce Clause of the
U.S. Constitution to preempt the power states usually have over matters of health
and safety and “prohibits interstate commerce in misbranded and adulterated
foods, drinks, and drugs.”93 This initial dual mission of protecting consumers
from false claims and unsafe products began a process that continues into the
present of Congress asserting more and more federal control over the
manufacturing and distribution of what it defines as “articles intended for use in
the diagnosis, cure, mitigation, treatment, or prevention of disease in man or
other animals.”94

may contain ingredients that are not meant for people to consume, and how these ingredients can
affect humans has not been studied.”).
89. Leana Wen, The Checkup With Dr. Wen: Ivermectin (still) does not work against covid19, WASH. POST, https://s2.washingtonpost.com/camp-rw/?trackId=5a5b6ed1ade4e246b1fcd250
&s=624f4c6764253a7f3421612f&linknum=5&linktot=61 (last visited Apr. 8, 2022); Jennifer
Reich, Why vaccine skeptics are all in on ivermectin, WASH. POST (Sept. 7, 2021),
https://www.washingtonpost.com/outlook/2021/09/07/ivermectin-vaccine-skeptics/; Steven Chee
Loon Lim et al., Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild
to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial, 182 JAMA
INTERN. MED. 426–35 (2022).
90. WCYB, Tennessee Senate passes bill to allow ivermectin to be bought for COVID-19
treatment, ABC 13 NEWS (Apr. 6, 2022), https://wset.com/news/coronavirus/tn-senate-passeslegislation-to-allow-ivermectin-to-be-purchased-over-the-counter;
Adrianna
Rodriguez,
Lawmakers push legislation to protect doctors who prescribe ivermectin for COVID-19. Can they
do that?, USA TODAY (Mar. 10, 2022), https://www.usatoday.com/story/news/health/2022/
03/10/covid-ivermectin-bill-dozens-states-push-laws-protect-doctors/9356967002/.
91. Jennifer Reich, Why vaccine skeptics are all in on ivermectin, WASH. POST (Sept. 7,
2021), https://www.washingtonpost.com/outlook/2021/09/07/ivermectin-vaccine-skeptics/.
92. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq.
93. Milestones in U.S. Food and Drug Law, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/about-fda/fda-history/milestones-us-food-and-drug-law (last updated Jan. 31,
2018).
94. 21 U.S.C. 321(g)(1)(B); see also Definition of a Drug (April 2017), U.S. FOOD & DRUG
ADMIN., https://www.fda.gov/drugs/fda-drug-info-rounds-video/definition-drug-april-2017 (last
updated Apr. 26, 2017).
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1. Federal Regulation of the Sale and Use of Prescription Drugs
Off-label prescribing is possible because, while the federal government has
preempted some of the states’ inherent power recognized by the 10th
Amendment to regulate matters of health and safety by vesting the FDA with
power to approve drugs, it has left states with the power to regulate the providers
who prescribe the drugs the FDA approves.95
Under the current system of regulation, the FDA has the authority to require
drug manufactures to “demonstrate, through clinical trials, the safety and
efficacy of a new drug for each intended use or indication.”96 Once this is proved
to the FDA’s satisfaction, it has the authority to make two decisions: first,
whether the drug should be available only through a prescription;97 and second,
what information must be included with the drug to provide doctors and patients
sufficient information to understand the terms of its approval.98 With the power
transferred from the FDA to the states comes the authority to prescribe an FDA
“approved drug” for “an unapproved use.”99
95. See Gibbons v. Ogden, 22 U.S. 1, 203 (1824) (describing state police power as an
“immense mass of legislation, which embraces every thing within the territory of a state, not
surrendered to the general government [including] [i]nspection laws, quarantine laws, health laws
of every description”); Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321(g)(1)(B) (The
FFDCA defines “drugs” as “articles” whose manufacturers claim are “intended for use in the
diagnosis, cure, mitigation, treatment or prevention of disease.”); Nadia N. Sawicki, Character,
Competence, and the Principles of Medical Discipline, 13 J. HEALTH CARE L. & POL’Y 285, 289–
94 (2010) (citing Dent v. West Virginia, 129 U.S. 114, 122 (1889)) (tracing state authority to
establish medical licensing boards through its history and practice); Human Drugs, U.S. FOOD &
DRUG ADMIN., https://www.fda.gov/industry/regulated-products/human-drugs (last updated on
Mar. 5, 2021); see also Jacobson v. Massachusetts, 197 U.S. 11, 25 (1905); U.S. Const. amend. X
(“The powers not delegated to the United States by the Constitution, nor prohibited by it to the
States, are reserved to the States respectively, or to the people.”); Elizabeth Weeks Leonard, State
Constitutionalism and the Right to Health Care, 12 U. PA. J. CONST. L. 1325, 1329–30 (2010) (“By
contrast to several state constitutions, the federal constitution does not expressly reference the word
‘health’ in any provision.”). Donald D. Ashley, Clarifying Misconceptions About US Food and
Drug Administration Unapproved Drugs Program, 127 ANESTHESIA & ANALGESIA 1292, 1292
(2018) (“Drug regulation was first brought under federal law in 1906 with passage of the original
Federal Food and Drug Act, which prohibited the sale of adulterated and misbranded drugs, but did
not require drugs be preapproved by the FDA.”); Mut. Pharm. Co. v. Bartlett, 570 U.S. 472, 486–
87 (2013) (the FDCA preempts state law when it is impossible for drug manufacturers to comply
with the laws of different states simultaneously).
96. United States v. Caronia, 703 F.3d 149, 153 (2d Cir. 2012) (citing 21 U.S.C. §
355(d)); see Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609, 612–14, (1973).
97. United States v. Caronia, 703 F.3d 149, 152–53 (2d Cir. 2012) (citing 21 U.S.C. § 355(a))
(“The FDCA [requires that] before drugs are distributed into interstate commerce, they must be
approved by the FDA for specific uses.”).
98. See id. at 154; see also Lars Noah, Constraints on the Off-Label Uses of Prescription
Drug Products, 16 J. PRODS. & TOXICS LAB 139, 141 (1994) (off label prescribing can also involve
using a different method of delivering the drug to the patient than was approved in the original
approval process such as a drug approved for oral use being given intravenously).
99. See Understanding Unapproved Use of Approved Drugs “Off Label,” U.S. FOOD & DRUG
ADMIN., https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options
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Over time, the FDA’s mandate expanded beyond assuring safety so that today
it has the legal authority to determine whether the drugs, biologics, and vaccines
it regulates are also effective for their approved “specific uses.”100 The FDA
also has the authority to designate whether a drug “requires a doctor’s
authorization to purchase.”101 If the FDA concludes that the evidence provided
by the entity seeking approval of the drug—the “sponsor” or “manufacturer”—
is adequate, then the last step is for the FDA to announce the conditions under
which it can be sold to the public. These conditions of use are referred to as the
“label” even though they are printed on separate sheets of paper, not actually
attached to the bottle The label includes the FDA’s decision about whether the
drug can be made available through direct purchase by a consumer or through
the order of a licensed prescriber.102 The end of this labeling process marks the
end of the FDA’s oversight and the beginning of state control.103

/understanding-unapproved-use-approved-drugs-label (last updated Feb. 5, 2018); see also OffLabel Drugs: What You Need to Know, AGENCY FOR HEALTHCARE RSCH. & QUALITY,
https://www.ahrq.gov/patients-consumers/patient-involvement/off-label-drug-usage.html
(last
updated Sept. 2015) (“Off-label prescribing is when a physician gives you a drug that the U.S. Food
and Drug Administration (FDA) has approved to treat a condition different than your condition.
This practice is legal and common. In fact, one in five prescriptions written today are for off-label
use.”).
100. Janet Woodcock, M.D., Safety, Efficacy, and Quality Remain Top Priorities as We
Continue Our Work to Expand Access to Cost-Saving Generic Drugs for the American Public, U.S.
FOOD & DRUG ADMIN. (May 13. 2019), https://www.fda.gov/news-events/fda-voices/safetyefficacy-and-quality-remain-top-priorities-we-continue-our-work-expand-access-cost-saving.
101. See Drugs@FDA Glossary of Terms, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/
drugs/drug-approvals-and-databases/drugsfda-glossary-terms#P (choose letter “P” from glossary
selection; then scroll to the definition for “Prescription Drug Product”) (last updated Nov. 14,
2017).
102. See 21 U.S.C. § 353(b)(1) (“A drug intended for use by man which because of its toxicity
or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary
to its use, is not safe for use except under the supervision of a practitioner licensed by law to
administer such drug.”).
103. See 21 U.S.C. § 355-1(f)(1) (The FDA has limited authority to restrict the terms under
which providers can prescribe drugs by making “Elements to Assure Safe Use” as part of the label.
It also has limited authority to initiate an action to withdraw approval if there is substantial evidence
that the drug is harmful in ways not revealed during testing); see also Understanding Licensing,
Credentialing, Certification, and Privileging, ASS’N OF STATE AND TERRITORIAL HEALTH OFFS.,
https://astho.org/Programs/Preparedness/Public-Health-Emergency-Law/Scope-of-PracticeToolkit/Understanding-Licensing,-Credentialing,-Certification,-and-Privileging(2) (last visited
Aug. 2, 2020); see also Jennifer S. Bard, Putting Patients First: How the FDA Could Use Its
Existing Powers to Reduce Post-Market Adverse Events, 10 IND. HEALTH L. REV. 495, 516–17
(2013) (“Once the FDA approves a drug or device is then that it becomes available for any
physician to prescribe to any patient.”).
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2. State Regulation of Prescribing Authority
Congress has been explicit that the FDA’s authority extends only to the
regulation of drugs, not to the regulation of the practice of medicine.104 States
retain their power over the use of prescription drugs so long as they do not 1) act
in a way that undermines the federal government’s authority under the FDA;105
and 2) obey the additional restrictions that Congress has placed on prescribing
drugs that have been designated as especially dangerous and subject to criminal
diversion.106 Other than these two provisions, states can decide both who can
prescribe drugs,107 and the criteria for doing so.108 The restrictions that do exist
under state law involve additional procedures for drugs that are likely to be
abused.109 Today, all states extend full prescribing power beyond M.D.s, to
include osteopaths, dentists, veterinarians (for animals), and nurse

104. See 21 U.S.C. § 396 (“Nothing in this chapter shall be construed to limit or interfere with
the authority of a healthcare practitioner to prescribe or administer any legally marketed device to
a patient for any condition or disease within a legitimate healthcare practitioner-patient
relationship.”); see also George Horvath, Off-Label Drug Risks: Toward a New FDA Regulatory
Approach, 29 ANNALS HEALTH L. 101, 116 (2020) (“In general, the Agency has eschewed attempts
at directly prohibiting physicians from prescribing drugs for off-label indications.”); see generally
Jeffrey K. Aronson & Robin E. Ferner, Unlicensed and Off-Label Uses of Medicines: Definitions
and Clarification of Terminology, 83 BRITISH J. CLINICAL PHARMACOLOGY 2615, 2616, 2618
(2017) (In contrast, in the United Kingdom the same entity licenses physicians and oversees drug
approval allowing for a more coordinated approach).
105. See generally Elizabeth Y. McCuskey, Body of Preemption: Health Law Traditions and
the Presumption of Against Preemption, 89 TEMP L. REV. 95, 114–117 (2016) (tracing development
of application of health regulation activities to the Police Power).
106. Mut. Pharm. Co. v. Bartlett, 570 U.S. 472, 495–96 (2013) (the FFDCA preempts state law
when it is impossible for drug manufacturers to comply with the laws of different states
simultaneously).
107. This is an on-going process and the laws in any particular state are likely to be different
at any specific time. See State Law Fact Sheet: A Summary of Nurse Practitioner Scope of Practice
Laws, in Effect April 2016, CTRS. FOR DISEASE CONTROL & PREVENTION, https://www.cdc.gov/
dhdsp/pubs/docs/SLFS_NSOP_508.pdf (last accessed Feb. 18, 2022); see also State Practice
Environment, AM. ASSOC. OF NURSE PRACTITIONERS, https://www.aanp.org/advocacy/state/statepractice-environment (last accessed July 29, 2020); see, e.g., Who Can Prescribe and Administer
Prescriptions in Washington State, WASH. STATE DEP’T OF HEALTH, https://www.doh.wa.gov/
LicensesPermitsandCertificates/ProfessionsNewReneworUpdate/PharmacyCommission/WhoCan
PrescribeandAdministerPrescriptions (last accessed July 29, 2020).
108. Every state has laws intended to reduce opioid deaths by limiting the prescription of
opioids. For an overview of state laws, see Prescription Drug Time and Dosage Limit Laws, CTRS.
FOR DISEASE CONTROL & PREVENTION, (Mar. 5, 2015), https://www.cdc.gov/phlp/docs/
menu_prescriptionlimits.pdf; Marilyn Bulloch, Opioid Prescribing Limits Across the States,
PHARM. TIMES (Feb. 5, 2019), https://www.pharmacytimes.com/contributor/marilyn-bullochpharmd-bcps/2019/02/opioid-prescribing-limits-across-the-states.
109. See, e.g., N.J. ADMIN. CODE § 13:35-7.8(a) (2022) (“A practitioner shall not prescribe,
order, dispense, administer, sell or transfer any amphetamine or sympathomimetic amine
designated as a Schedule II controlled substance for use in weight management, dieting or any other
anorectic purpose, or for the treatment of fatigue.”).
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practitioners.110 In addition, many states have extended limited, Second Tier
prescribing privileges to physician’s assistants, Certified Registered Nurse
Anesthetists, Naturopathic Doctors, Optometrists, psychologists, and
Pharmacists.111
B. How Common is Off-Label Prescribing?
By some estimates, as many as one in five prescriptions in the United States
are “written ‘off-label.’”112 While there is wide agreement that prescribing drugs
off-label is a longstanding and deeply embedded part of clinical practice in the
United States, exactly how much and by whom is hard to determine. There is
no generally accepted number of annual off-label prescriptions. By some
estimates as many as 30% of all prescriptions are off-label and in fields like
oncology, the number is likely much higher.113 The most commonly reported
areas for off-label prescribing are in oncology, dermatology,114 palliative
110. For a history of the development of the profession of nurse practitioners, see John Michael
O’Brien, How Nurse Practitioners Obtained Provider Status: Lessons for Pharmacists, 60 AM. J.
HEALTH SYS. PHARM. 2310 (2003), https://www.medscape.com/viewarticle/464663_2; For a 50
state survey of the extent to which Nurse Practitioners have prescriptive authority, see State Law
Chart: Nurse Practitioner Prescriptive Authority, AM. MED. ASS’N, https://www.amaassn.org/sites/ama-assn.org/files/corp/media-browser/specialty%20group/arc/ama-chart-npprescriptive-authority.pdf (last visited Feb. 18, 2022).
111. Prescriptive
Authority,
MED.
DICTIONARY
(2009),
https://medicaldictionary.thefreedictionary.com/prescriptive+authority; State Approaches to Scope of Practice:
Certified Registered Nurse Anesthetists, ARK. CTR. FOR HEALTH IMPROVEMENT,
https://achi.net/library/scope-of-practice-nurse-anesthetist/ (accessed Aug. 2, 2020); Do
Naturopathic Doctors Prescribe Medication?, INST. FOR NAT. MED., https://naturemed.org/faq/donaturopathic-doctors-prescribe-medication (last accessed Aug. 2, 2020); Winter 2007/Spring 2008
Newsletter, Drugs That May be Prescribed by Optometrists, TEX. STATE BD. OF PHARMACY,
https://www.pharmacy.texas.gov/files_pdf/Optometrists.pdf (last accessed Aug. 2, 2020),
http://web.archive.org/web/20200304113303/https://www.pharmacy.texas.gov/files_pdf/Optomet
rists.pdf; David J. Reinhardt, Psychologist’s Prescribing: A Threat or a Promise, MEDSCAPE (June
24, 2010) https://www.medscape.com/viewarticle/723997_2; Gloria Sachdev et al., Current Status
of Prescriptive Authority by Pharmacists in the United States, 3 J. AM. COLL. OF CLINICAL
PHARMACY 807 (2020).
112. Carah Wertheimer, 1-in-5 Prescriptions Are Off-Label: What You Don’t Know Could
Hurt You, MEDTRUTH.COM (Mar. 17, 2020), https://medtruth.com/articles/health-features/offlabel-prescriptions/; Off-Label Drugs: What You Need to Know, AGENCY FOR HEALTHCARE RSCH.
& QUALITY, https://www.ahrq.gov/patients-consumers/patient-involvement/off-label-drug-usage.
html (last accessed July 26, 2020).
113. Shariful A. Syed, Brigham A. Dixson, Eduardo Constantino & Judith Regan, The Law
and Practice of Off-Label Prescribing and Physician Promotion, 50 J. AM. ACAD. PSYCHIATRY &
L. 1, 2 (2021), http://jaapl.org/content/early/2020/11/24/JAAPL.200049-20 (“In recent studies in
community clinical practices, 40 to 80 percent of recipients of commonly prescribed psychotropic
medications (including antidepressants, antipsychotics, and anticonvulsants) were receiving these
medications for off-label indications”)(citing J. Wong, A. Motulsky & M. Abrahamowicz, OffLabel Indications For Antidepressants In Primary Care: Descriptive Study Of Prescriptions From
An Indication Based Electronic Prescribing System, 356 BMJ 603 (2017).
114. Katelin França & Sergio Litewka, Controversies in Off‐label Prescriptions in
Dermatology: The Perspective of the Patient, the Physician, and the Pharmaceutical Companies,
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medicine,115 and psychiatry.116 One specialty that was, until recently, almost
completely dependent on off-label drugs was pediatrics. In a report
accompanying amendments to the Federal Food, Drug, and Cosmetics Act,
Senator Jim Jeffords wrote, “[c]hildren have for years been wrongly considered
‘small adults’ when estimating the effect of prescription drugs on their overall
health. Currently there is no systematic means for testing the safety and efficacy
of drugs on the pediatric population.”117
Because there is nothing illegal about off-label prescribing, there are no
requirements to monitor it. Some estimates of which drugs are most commonly
prescribed for which conditions have come from analyzing the Medicare
prescribing records,118 but currently most estimates are based on surveys of
prescribers themselves.119 But while there is no precise information about how
many patients receive drugs off-label, there is strong and consistent evidence
that doctors believe that off-label prescribing is an essential part of practicing
medicine.120 Oncologists, by some estimates prescribe as much as eighty
percent of medications off label, contend that developments move so quickly,
and their patients are so sick that they cannot wait for final approval.121

58 INT’L J. DERMATOLOGY 788, 789 (2019) (“It is estimated that 21% of the prescriptions in the
United States are off-label . . . Off-label prescribing involved an unapproved indication in 56.4%
of cases, a lower dosage (26.5%) or higher dosage (19.5%) than speciﬁed, age not labeled (7.2%),
incorrect route of administration (3.5%), and contraindication (0.3%)”).
115. Vera Hagemann et al., Drug Use Beyond the License in Palliative Care: A Systematic
Review and Narrative Synthesis, 33 PALLIATIVE MED. 650, 655 (2019).
116. Aishwarya Vijay et al., Patterns and Predictors of Off-Label Prescription of Psychiatric
Drugs, 13 PLOS ONE 1, 2 (2018) (“This practice is legal and common⎯a 2003 report showed that
for the 3 leading drugs in each of the 15 leading drug classes, off-label use accounted for
approximately 21% of prescriptions.”).
117. S. REP. NO. 105-43, at 3 (1997).
118. Christopher C. Yang & Mengnan Zhao, Determining Associations with Word Embedding
in Heterogeneous Network for Detecting Off-Label Drug Uses, IEEE COMPUTER SOCIETY (2017),
http://ieeexplore.ieee.org/stamp/stamp.jsp?tp=&arnumber=8031200&isnumber=8031114.
119. Christopher C. Yang & Mengnan Zhao, Determining Associations with Word Embedding
in Heterogeneous Network for Detecting Off-Label Drug Uses, IEEE COMPUTER SOCIETY (2017),
http://ieeexplore.ieee.org/stamp/stamp.jsp?tp=&arnumber=8031200&isnumber=8031114.
W. David Bradford et al., Off-Label Use of Pharmaceuticals: A Detection Controlled Estimation
Approach, 66 J. INDUS. ECON. 866 (2018); Aviv Ladanie et al., Off-label Treatments Were Not
Consistently Better or Worse than Approved Drug Treatments in Randomized Trials, 94 J.
CLINICAL EPIDEMIOLOGY 35 (2018).
120. George Horvath, Off-Label Drug Risks: Toward a New FDA Regulatory Approach, 29
ANNALS HEALTH L. 101, 110−11 (2020) (“Data reported in 2003 indicated that, overall, twentytwo percent of all prescriptions were for off-label indications. In some patient groups, this number
may exceed seventy percent.”).
121. See generally I. Glenn Cohen, Therapeutic Orphans, Pediatric Victims? The Best
Pharmaceuticals for Children Act and Existing Pediatric Human Subject Protection, 58 FOOD &
DRUG L.J. 661, 661 (2003) (describing the development of regulations encouraging increased
research on pediatric drug safety and expressing concerns that it would have the consequence of
putting more children at risk as research subjects). See also Off-label Drug Use, AM. CANCER
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C. Safety Concerns Regarding Off-Label Prescribing
A recent report to Congress on its options for regulating off-label prescribing
listed ten different “[p]ossible [a]venues of [f]uture [c]ongressional [i]nterest”
based on concerns that the current system risked the safety of patients because
it evades current laws requiring that drugs be proved safe and effective by the
FDA.122 Regulators, patient advocates, and physicians themselves express
concerns about off-label prescribing as it exposes patients to risks from drugs,123
which have not been found by the FDA to be safe and efficacious for them. 124
Speaking in the context of widespread publicity about the harm caused by offlabel prescription of two FDA approved medications for weight loss, bioethicists
Rebecca Dresser and Joel Frader warned that “[o]ff-label prescribing can expose
patients to risky and ineffective treatments.”125 A recent Congressional Research
Service (CRS) report notes that after the first reports of success with using
intravenous ketamine for the treatment of depression and migraines, physicians
were able to set up commercial clinics even though the FDA had not yet
“reviewed clinical data that could support the clinics’ promotional claims of
safety and effectiveness.”126 By some estimates, less than half of the clinical
trials approved by the FDA result in petitions for approval.127 The FDA reports
that between 2011 and 2018 it “approved 309 novel drugs, of which 261 (84%)
SOC’Y, https://www.cancer.org/treatment/ treatments-and-side-effects/treatment-types/off-labeldrug-use.html (last accessed July 26, 2020).
122. See Susan Thaul, CONG. RSCH. SERV., R45792, OFF-LABEL USE OF PRESCRIPTION
DRUGS 9–12 (2019).
123. Id. at 9, 14 (“Prescriptions for off-label uses of FDA-approved drugs are made without
the benefit of an FDA-reviewed analysis of safety and effectiveness data.”).
124. Tewodros Eguale et al., Association of Off-label Drug Use and Adverse Drug Events in
an Adult Population, 176 J. AM. MED. ASS’N INTERNAL MED. 55, 55 (2015) (exploring the risks
of off-label drug use in Canada).
125. Rebecca Dresser & Joel Frader, Off-Label Prescribing: A Call for Heightened
Professional and Government Oversight, 37 J.L. MED. & ETHICS 476, 476–78 (2009) (describing
physicians’ discretion in prescribing drugs at dosages or using methods of administration not
specified on the label).
126. Susan Thaul, CONG. RSCH. SERV., R45792, OFF-LABEL USE OF PRESCRIPTION DRUGS
1–3 (2019) (“In a 2006 study of drug prescribing by office-based physicians, 21% of prescriptions
were written for off-label uses. Of those off-label prescriptions, the study’s authors found that 27%
were backed by strong scientific support. A 2016 Canadian study of primary care clinics found an
overall rate of 12% of prescriptions for off-label uses. The percentage varied, however, by
therapeutic class, ranging from 5% for ear, nose, and throat medications to 25% for central nervous
system medications. An econometric model from the National Ambulatory Medical Care Survey
estimated a 38% rate of off-label use.”).
127. Asher Mullard, 2021 FDA Approvals, NATURE (Jan. 19, 2022), https://www.nature.com/
articles/d41573-022-00001-9#:~:text=The%20FDA’s%20approval%20count%20last,at%2051%
20drugs%20per%20year; Angelika Batta, Bhupinder Singh Kalra & Raj Khirasaria, Trends in FDA
drug approvals over the last 2 decades: An observational study, 9 J. FAM. MED. PRIMARY CARE
105 (2020), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014862/; Is it true FDA is approving
fewer new drugs lately?, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/media/
80203/download.
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were approved” the first time they were submitted.128 But this reflects only
drugs that made it to the end of a very long process. While there is no official
data, one commonly repeated estimate is that “[o]nly 5 in 5,000 drugs that enter
preclinical testing progress to human testing. One of these 5 drugs that are tested
in people is approved.”129 The result of this process, established by federal law
and funded by Congress, is to limit the drugs available for sale in the United
States to those which have been proven safe and effective for specific purposes.
While the FDA neither initiates nor solicits companies to develop drugs, its
standards guide the behavior of private drug companies in deciding which drugs
to advance through development, first in the lab and then animal testing, before
submitting an application for approval to begin testing in humans.130 Moreover,
the longer a drug is used off-label, the less likely that any such review will ever
occur because there is little financial incentive to do so.131
D. Lack of Information Sufficient for Providers to Obtain Informed Consent
from Patients
Physicians have a fiduciary duty to provide patients with enough information
so that they can make informed decisions about their care.132 In the case of
prescription drugs, the information available to the physician is the FDA “label,”
which describes the purpose for which the FDA has issued approval in terms of
the kind of condition to be treated and the category of patient.133 Moreover,
consumer research suggests that there is very little public awareness of the
difference in what is known about the risks and benefits of a drug used off-label
as opposed to one that has been FDA approved.134

128. U.S. FOOD & DRUG ADMIN., ADVANCING HEALTH THROUGH INNOVATION – NEW DRUG
THERAPY APPROVALS 2019 24 (2020), https://www.fda.gov/media/134493/download.
129. See Drug Approvals – From Invention to Market . . . A 12-Year Trip, MEDICINENET,
https://www.medicinenet.com/script/ main/art.asp?articlekey=9877 (last updated July 14, 1999);
see also U.S. FOOD & DRUG ADMIN., The Drug Development and Approval Process,
https://www.fda review.org/issues/the-drug-development-and-approval-process (last visited July
26, 2020).
130. Susan Thaul, CONG. RSCH. SERV., R45792, OFF-LABEL USE OF PRESCRIPTION DRUGS 6
(2019) (“The FDA-approved labeling, which informs the clinician about dosing and likely and
unlikely adverse events, helps protect the individuals for whom the drug is prescribed.”).
131. Id. at 6 (“Once drugs are well established in off-label uses, manufacturers rarely design
studies to determine or verify the safety and effectiveness of such uses.”).
132. The Fiduciary Relationship, THE CLIMATE CHANGE AND PUBLIC HEALTH LAW SITE
https://biotech.law.lsu.edu/books/lbb/x236.htm (last visited Apr. 8, 2022).
133. Are Too Many Kids Taking Antipsychotic Drugs?, CONSUMER REPORTS, (Dec. 2013),
https://www.consumerreports.org/cro/2013/12/are-too-many-kids-taking-antipsychoticdrugs/index.htm.
134. See Jesse R. Catlin & Cornelia Pechmann, An Investigation of Consumer and Doctor
Regulatory Beliefs and Regulatory Knowledge about Pharmaceutical Drug Promotions, 1 J. ASS’N
FOR CONSUMER RSCH. 392, 403 (2016); see SUSAN THAUL, CONG. RSCH. SERV., R45792, OFFLABEL USE OF PRESCRIPTION DRUGS 9 (2021) (“Most individuals, unaware of the nuances of FDA
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This lack of information is exacerbated by the lack of any legal requirement
that a physician inform a prospective patient that they are prescribing the drug
off-label.135 Without knowing that a drug has not been reviewed by the FDA for
use to treat their condition, the patient may assume that their prescriber is fully
informed about the risks and benefits of this particular drug for their specific
condition.136 As a consumer advocate testified in 2016 to an FDA panel on use
of off-label medical devices:
Patients should have informed consent, which includes signing a piece
of paper that explains that the product is not approved by the FDA for
the indication that the product is being prescribed for. It should also
include a discussion of what that means regarding the lack of objective
evidence that the benefits outweigh the risks for most patients.137
In the absence of legal requirements to inform, advice on the FDA’s website
that patients “may want to consider” asking their “healthcare provider . . . about
using an approved drug for an unapproved risk” would only be relevant to
patients whose provider chose to inform them.138 As one critic puts it,
unrestricted prescribing privileges are “an anachronism” in that it assumes all
licensed prescribers have sufficient information to prescribe all FDA approved
drugs.139
One of the consequences of an absence of a legal requirement to inform
patients about off-label use is that very few doctors faced liability for harm
attributable to the drug so long as they acted according to the prevailing standard
of care.140
Commentators on the risks to physicians of prescribing
regulation, may not know that physicians may prescribe drugs for uses that FDA has not reviewed
for safety and effectiveness.”).
135. Margaret Z. Johns, Informed Consent: Requiring Doctors to Disclose Off-Label
Prescriptions and Conflicts of Interest, 58 HASTINGS L.J. 967, 967 (2007).
136. Testimony to FDA Panel on Consideration of Off-Label Promotion of Medical Devices,
PATIENT CONSUMER & PUB. HEALTH COALITION (Nov. 10, 2016) http://patientsandconsumers.org
/testimony-to-fda-panel-on-consideration-of-off-label-promotion-of-medical-devices/
(Jack Mitchell, the director of government relations for the non-profit National Center for Health
Research, made the point that the issue was of even greater concern for medical devices than for
drugs because “the vast majority” of approvals of medical devices are done without clinical trials).
137. Id.
138. See Understanding Unapproved Use of Approved Drugs “Off Label,” U.S. FOOD & DRUG
ADMIN. (Feb. 5, 2018), https://www.fda.gov/patients/learn-about-expanded-access-and-othertreatment-options/understanding-unapproved-use-approved-drugs-label (recommending seven
“questions” that a patient “may want to consider” asking their “healthcare provider . . . about using
an approved drug for an unapproved risks” which seek information such as “[w]hat scientific
studies are available to support the use of this drug to treat my disease or medical condition?”
available for FDA approved drugs being used for their intended uses but which are most likely
unavailable for off-label use.).
139. Phillip M. Rosoff & Dorianne Lambelet Coleman, The Case for Legal Regulation of
Physicians’ Off-Label Prescribing, 86 NOTRE DAME L. REV. 649, 659–60 (2011).
140. Katrina Furey & Kirsten Wilkins, Prescribing “Off-Label”: What Should a Physician
Disclose?, 18 AMA J. ETHICS 587, 590 (2016) (“Although many malpractice lawsuits have been
filed on behalf of patients arguing that they did not give informed consent to take a drug because
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hydroxychloroquine for COVID-19 concluded that they were low because “[t]he
drug itself has been publicly available for 70 years and has been found to be safe
with few side effects.”141 Therefore, a plaintiff would have to prove that
whatever harm they experienced was because of the hydroxychloroquine rather
than COVID-19.142
E. Distinguishing Off-Label Prescribing from Compassionate Use, Right to
Try, Clinical Research Trials, and Emergency Use Authorizations
1. Right to Try/Compassionate Use
Off-label prescribing involves a drug already approved by the FDA, but
patients often also seek access to drugs which have not been approved. Most
often, these requests come based on information about a clinical trial of an
experimental drug that has not yet completed the FDA process.143 If the trial is
still active, the patient’s doctor can petition the FDA for permission to have
access to the drug through its “Expanded Access” program.144 The doctor must
also seek permission from the company manufacturing the drug. In addition to
the FDA and the company, the request must be approved by the Institutional

they were not informed that use for their particular condition was actually off-label, the law has
generally sided with physicians in finding that they have no legal duty to inform patients of a drug’s
regulatory status.”).
141. Bernard M. Cassidy, Off-Label Prescribing for COVID-19: Is it Fraud?, LUBELL ROSEN,
LLC, https://lubellrosen.com/news-resources/post/-label-prescribing-covid-19-it-fraud (last visited
Aug. 2, 2020) (concluding that, when focusing on the CMS concern, the greater concern for those
prescribing “Chloroquine” is that it may run afoul of Center for Medicare and Medicaid rules about
reimbursement than about medical malpractice). See also Jennifer S. Bard, Human Subjects
Research in Emergencies: The Texas Nursing Home “Study” (Part II), BILL OF HEALTH (Apr. 27,
2020), https://blog.petrieflom.law.harvard.edu/ 2020/04/27/human-subjects-research-hydroxy
chloroquine-texas-covid19/#more-28705 (noting that it is likely that the “standard of care” for
prescribing hydroxychloroquine would be the one at the time of treatment and doctors would not
be held responsible for information that emerges later).
142. Melissa Pandika, A Nursing Home Gave Over 200 Residents Hydroxychloroquine
Without State Health Department Approval, MIC (July 29, 2020), https://www.mic.com/p/anursing-home-gave-over-200-residents-hydroxychloroquine-without-state-health-departmentapproval-30267352 (reporting administration of hydroxychloroquine to two-hundred and five
nursing home residents in Pennsylvania).
143. Patients also sometimes seek access to drugs which are no longer in the active process of
approval, either because the sponsor has withdrawn the application or the FDA has rejected it.
144. Barbara K. Redman & Alison Bateman-House, Institutional Review Boards as Arbiters
of Expanded Access to Unapproved Drugs: Time for a Change?, THERAPEUTIC INNOV. & REG.
SCI., 1 (2016), https://www.researchgate.net/profile/Alison-Bateman-House/publication/2938038
63_Institutional_Review_Boards_as_Arbiters_of_Expanded_Access_to_Unapproved_Drugs_Ti
me_for_a_Change/links/5a805fd80f7e9be137c8ef76/Institutional-Review-Boards-as-Arbiters-ofExpanded-Access-to-Unapproved-Drugs-Time-for-a-Change.pdf. The expanded access program
requires an individual doctor to make application to the FDA and seek permission from the
company manufacturing the drug. In addition to the FDA and the company, the request must be
approved by the Institutional Review Board overseeing the study.

Summer 2022]

The President's Remedy

455

Review Board overseeing the study.145 If the company and the FDA agree, the
company can only supply the drug at cost since it is not yet approved for sale.146
Although the FDA has approved almost every request that it receives, patient
advocacy groups have been very critical of the program.147 These groups have
been very successful in getting first individual states and now the federal
government to broaden the availability of unapproved drugs by passing laws that
purport to give drug companies additional permission that extend to patients
investigational drugs at the very earliest stages of testing. These are called
“Right to Try Laws” and, again, are intended to give patients access to drugs
before they are approved for any use.148 Whether these laws offer any additional
benefit to patients is a matter of considerable dispute. The nation’s leading
bioethics expert on these laws, Professor Holly Fernandez-Lynch, has explained
that “although terminally ill patients might assume they have nothing to lose by
trying an investigational treatment, this is not necessarily the case . . . . They
could take a medication that could make them die faster or in a worse way.”149
Right to Try laws have attracted the same kind of criticisms as off-label
prescribing because of concerns that the patients involved are very vulnerable to

145. Expanded Access: Information for Patients, U.S. FOOD & DRUG ADMIN. (last updated
Apr. 27, 2020), https://www.fda.gov/news-events/expanded-access/expanded-access-informationpatients.
146. Id.; Expanded Access and Right to Try: Access to Investigational Drugs, CONG. RSCH.
SERV. (Mar. 16, 2021), https://sgp.fas.org/crs/misc/R45414.pdf.
147. For example, an organization critical of the FDA’s practices is called Right To Try, see,
e.g., https://righttotry.org/about-right-to-try/. See Mark Flatten, DEAD ON ARRIVAL: FEDERAL
“COMPASSIONATE USE” LEAVES LITTLE HOPE FOR DYING PATIENTS 2 (GOLDWATER INST. ed.,
2016),
https://goldwaterinstitute.org/wp-content/uploads/2016/02/Dead-On-Arrival-Report.pdf
(“[T]he entire system for gaining access to an unapproved medication is so rigged with bureaucracy
and disincentives that it is bound to fail in most cases. Critics say it was designed that way, ensuring
that only a tiny number of patients are able to navigate the complex, costly, and time-consuming
maze that must be cleared just to file a compassionate use application for the FDA to consider.”).
148. Right to Try, U.S. FOOD & DRUG ADMIN. (last updated Jan. 14, 2020),
https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try.
149. Jennifer Byrne, Right to Try: A ‘Well-Intentioned’ but ‘Misguided’ Law, HEMONC TODAY
(Mar. 10, 2020), https://www.healio.com/news/hematology-oncology/20200303/right-to-try-awellintentioned-but-misguided-law. She also notes that pursuing an investigational treatment when
there is really no hope that it will be effective could also mean “They might be losing valuable time
with their families, or they might be missing out on palliative options.” Arthur Caplan is another
ethicist highly skeptical of Right to Try laws which he describes as “ballyhoo and hype” which are
unlikely to help because “[t]he FDA does not make or control access to unapproved drugs. Those
drugs are the property of the drugs’ sponsors: companies and academic institutions and their
investors. The FDA can’t make them give anything to anyone.” Arthur L. Caplan, “Right-to-Try”
Laws Provide Little Access to Investigational Drugs. We Created a Process that Does, STAT (June
3, 2019), https://www.statnews.com/2019/06/03/effective-ethical-right-to-try-process/.
See Arthur Caplan, “Right-to-Try” Laws Provide Little Access to Investigational Drugs. We
Created a Process that Does, STAT NEWS (June 3, 2019), https://www.statnews.com/2019/06/
03/effective-ethical-right-to-try-process/.
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over valuing the benefits and minimizing the risks.150 Moreover, there is no real
“right” granted by these laws since neither the federal nor state version impose
any obligations on the manufacturers who control access. At best, these laws
make access more attractive to manufacturers by providing them with immunity
from negligence liability if the product causes harm and by prohibiting the FDA
from using data generated by granting access as a reason to later grant
approval.151 In particular, there is concern that drug companies themselves are
not obligated to share information they know about risks directly with
patients.152 Also, both Extended Use and Right to Try statutes require that the
patient be very sick with no other options. There are no such requirements for
physicians prescribing drugs off-label.153
2. Emergency Use
The Emergency Use Authorization process was developed by the FDA to
accommodate the need of the Department of Defense to comply with a federal
law that limits the ability of the military to administer off-label drugs and
vaccines to active-duty personnel.154 It allows the FDA on its own or at the
request of the Department of Defense to temporarily change the terms of a label
in order to make it available on an emergency basis. Although developed in
response to the military’s need to combat anthrax during the Gulf War, today it
is available in any urgent situation where the FDA thinks it appropriate to avoid
the consequences of off-label use. In the case of hydroxychloroquine, the FDA
issued an EUA permitting its use so that the drug could be added to the national
strategic stockpile. Individual physicians already had authority to prescribe
hydroxychloroquine off-label. An EAU can also be issued to grant temporary
approval to use a drug that has not yet been approved for any purpose.155
3. Distinction Between Clinical Trials and Off-Label Prescribing
Another pathway for a patient to get a drug before it is approved is to be
enrolled in a clinical drug trial.156 While there are certainly many barriers to
entry to a clinical trial, such as those documented in the early days of HIV/AIDs

150. Jennifer Byrne, Right to Try: A ‘Well-Intentioned’ but ‘Misguided’ Law, HEMONC
TODAY (Mar. 10, 2020), https://www.healio.com/news/hematology-oncology/20200303/right-totry-a-wellintentioned-but-misguided-law.
151. Investigational Drugs for use by Eligible Patients, 21 U.S.C. § 360bbb-0a (2020).
152. See Lars Noah, Informed Consent and the Elusive Dichotomy Between Standard and
Experimental Therapy, 28 AM. J. L. & MED. 361, 364 (2002).
153. IND Safety Reporting, 21 C.F.R. § 312.32 (2020).
154. See Jennifer Bard, Why the Military Can Use Emergency Powers to Treat Service
Members with Trial COVID-19 Drugs, THE CONVERSATION (May 11, 2020, 7:49 AM),
https://theconversation.com/why-the-military-can-use-emergency-powers-to-treat-servicemembers-with-trial-covid-19-drugs-135876.
155. Id.
156. See Noah, supra note 152, at 361.
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drug development,157 once enrolled, those taking experimental drugs are
carefully monitored.158 A participant in a clinical drug trial can only enroll after
the proposed study is reviewed by an ethics board.159 Part of that review
involves assuring that the participant is fully informed of the risks associated
with the drug under study, the options for seeking treatment outside the study,
and the assurance that they can leave the study at any time.160 Moreover, while
they are enrolled, there is real-time monitoring for any “adverse events”
experienced by any participant.161
III. FEATURES OF OFF-LABEL PRESCRIBING
A. How Do Pharmaceutical Company Market Off-Label Use?
Much of the available information about action by pharmaceutical companies
to promote off-label use of their products comes from whistleblower complaints
brought to the Department of Justice.162 A study of these identified three main
categories of actions taken by pharmaceutical companies to increase off-label
use of their products.
A study of whistleblower complaints against pharmaceutical companies
revealed many of the tactics used by pharmaceutical companies to extend the
use of their drugs without running afoul of the prohibition against direct
marketing. It found the companies worked directly with doctors to identify
patients already in their practices who might be targets for off-label
prescription.163
Based on existing research into the practices of pharmaceutical companies
whose products are frequently used off-label, it is possible to see current efforts
to promote off-label COVID-19 treatments by targeting not just the doctors who
can freely prescribe them but the much larger group of patients who can ask for
them.
157. John E. Osborn, Can I Tell You the Truth? A Comparative Perspective on Regulating
Off-Label Scientific and Medical Information, 10 YALE J. HEALTH POL’Y L. & ETHICS 299, 333
(2010) (citing the delays in FDA approval to the first HIV/AIDS drugs as a justification for allowing
off-label prescribing).
158. See Noah, supra note 152, at 362.
159. U.S. DEP’T OF HEALTH & HUM. SRVS. OFFICE FOR HUM. RSCH. PROTECTIONS,
INSTITUTIONAL REVIEW BOARD (IRB) WRITTEN PROCEDURES: GUIDANCE FOR INSTITUTIONS
AND IRBS (2018), https://www.fda.gov/media/99271/download.
160. Informed Consent, U.S. FOOD & DRUG ADMIN. (July 2014), https://www.fda.gov/
regulatory-information/search-fda-guidance-documents/informed-consent.
161. Adverse Event Reporting to IRBs—Improving Human Subject Protection, U.S. FOOD &
DRUG ADMIN. (Jan. 2009), https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/adverse-event-reporting-irbs-improving-human-subject-protection.
162. Aaron S. Kesselheim et al., Strategies and Practices in Off-Label Marketing of
Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints, 8 PLOS MED. 1, 1
(2011), https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000431.
163. Id. at 5.
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B. What is the Patient Demand for Off-Label Drugs?
While there has long been concern that the involvement of pharmaceutical
companies in patient advocacy groups encouraged the kind of information
sharing that leads to requests for off-label prescriptions,164 the size of COVID19 market for off-label use of pharmaceutical products illuminates the issue to a
brightness that can no longer be avoided.
To spend time in the world of those in need of compassionate use waivers for
INDS or off-label use of an already approved drug is to be immersed in sorrow.
It is a world of patients and families and doctors who in the face of serious pain,
disability, and risk of death have tried all available options without finding any
relief.165 Some criticize that the pharmaceutical industry has encouraged
patients to advocate for off-label use.166 Patients have been encouraged to
believe that the drug approval process is too cumbersome to allow testing
beyond the minimum required for approval, but that based on the inside/deep
knowledge of the company who invented the drug it can help those far beyond
those for which it was first approved.167 In a striking parallel to today’s
circumstances, in the late 1980s the world was confronted with the arrival of
another deadly virus for which there was no effective treatment or vaccine. The
process of developing effective drugs to combat HIV has been retold many times
from many different perspectives. Moreover, by definition there was no
available information on long term use. As John Osborn describes it,
each public release of new long-term clinical data is eagerly
anticipated and received at prominent medical conferences by

164. A 2017 article in the New England Journal of Medicine reviewed current concerns about
the potential “conflicts-of-interest” related to promoting off-label prescribing which are present
when “industry-supported patient-advocacy organizations have spoken out for access to drugs with
questionable therapeutic benefit.” Matthew S. McCoy et al., Conflicts of Interest for PatientAdvocacy Organizations, 376 NEW ENG. J. MED. 880, 880 (2017), https://www.nejm.org/doi/full/
10.1056/NEJMsr1610625 (the article also considered another frequent concern about the extent to
which these organizations were sponsored by pharmaceutical companies which was that these
organizations “remained silent on policy proposals, such as drug-pricing reforms, that might benefit
their constituents.”). This article relies on a 2009 report by the Institute of Medicine calling for
legislation mandating this disclosure. CONFLICT OF INTEREST IN MEDICAL RESEARCH,
EDUCATION, AND PRACTICE (Bernard Lo & Marilyn J. Field eds., 2009).
165. Emily Kopp et al., Patient Advocacy Groups Take In Millions From Drugmakers. Is There
A Payback?, WASH. POST (Apr. 6, 2018), https://www.washingtonpost.com/national/healthscience/patient-advocacy-groups-take-in-millions-from-drugmakers-is-there-a-payback/2018/04/
06/0a75f988-397b-11e8-af3c-2123715f78df_story.html; see also Elisabeth Rosenthal, AN
AMERICAN SICKNESS: HOW HEALTHCARE BECAME BIG BUSINESS AND HOW YOU CAN TAKE IT
BACK (2017).
166. Michelle Llamas, Misplaced Trust: Why FDA Approval Doesn’t Guarantee Drug Safety,
DRUGWATCH (Aug. 30, 2021), https://www.drugwatch.com/featured/misplaced-trust-fdaapproval-concerns/.
167. Katharine Freeman, Upsetting the Balance with ‘Right to Try,’ PENN LDI (Jan. 18, 2018),
https://ldi.upenn.edu/healthpolicysense/upsetting-balance-right-try; Howard Wolinsky, Disease
Mongering and Drug Marketing, 6 EMBO REPS. 612 (2005)
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physicians who treat patients with HIV. With each release of data,
there is a pattern of information migration that runs from the company
to conference attendees, to publication in peer-reviewed medical
journals in the United States and abroad, to submission by the
company to various regulatory authorities around the world.168
The increasing research into the practice of off-label prescribing has found
that these prescriptions are often not safe or effective. In contrast to prescribing
a newly approved drug about which the only information is that presented to the
FDA for approval, many drugs prescribed off-label are well known. For
example, a recent study of psychiatric visits found that patients were being
prescribed drugs to treat conditions despite existing evidence that they did not
work.169 They noted that for one drug in particular, trazodone, not only was its
“efficacy . . . in the treatment of primary insomnia” weak, it also “has been
shown to be associated with a higher risk of adverse drug events” than already
approved FDA drugs.170
C. How Do Pharmaceutical Companies Make Money From Off-Label
Prescribing?
At the time President Trump was hawking hydroxychloroquine, there were no
vaccines available outside of a research study making the at-risk population
equal to that of the population living on Earth. This dwarfs even the largest
population of potential consumers of prescription drugs such as those with high
blood pressure, diabetes, cancer, or depression.
Despite all the criticism of limiting off-label prescribing, attempts at selfregulation have failed because the practice is so lucrative. The pharmaceutical
companies who make and market prescription drugs share with other entities an
inherent financial interest in expanding the market for their products, but the
legal compromise that allows off-label prescribing also imposes severe
restrictions on their ability to promote uses beyond those already approved by
the FDA.
The benefit of off-label prescribing is that it provides tremendous cost-savings
to drug companies because it significantly reduces the always considerable cost
of getting a new drug approved by the FDA.171 With the option of off-label
prescribing, they can test drugs on relatively healthy patients, who are unlikely
168. John E. Osborn, Can I Tell You the Truth? A Comparative Perspective on Regulating
Off-Label Scientific and Medical Information, 10 YALE J. HEALTH POL’Y L. & ETHICS 299, 333
(2010).
169. Aishwarya Vijay et al., Patterns and Predictors of Off-Label Prescription of Psychiatric
Drugs, 13 PLOS ONE 1, 2 (2018) (“This practice is legal and common⎯a 2003 report showed that
for the 3 leading drugs in each of the 15 leading drug classes, off-label use accounted for
approximately 21% of prescriptions.”).
170. Id. at 7.
171. Elizabeth Richardson, Off-Label Drug Promotion, HEALTH AFFS. (June 30, 2016),
https://www.healthaffairs.org/do/10.1377/hpb20160630.920075/full/.
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to die or experience inconvenient adverse events during the trial process with
the knowledge that once it is approved, it can be prescribed widely.172 This
financial incentive to promote off-label use is of particular concern when there
are safe and effective drugs available.
The true scope and nature of off-label prescribing is proprietary to the
companies who stand to benefit financially: the companies that make drugs most
frequently prescribed for purposes other than those for which FDA permission
was originally obtained.173
The light cast on off-label prescribing by hydroxychloroquine’s remarkable
trajectory in first being hawked by the leader of the United States and then within
months renounced by the FDA and the World Health Organization provides an
opportunity to discuss a practice usually occurring in the shade cast by the
protection pharmaceutical companies have for proprietary sales data.174 As a
result, specific information about which drugs are prescribed in the United States
for purposes other than those for which they were approved by the FDA comes
from the partial records available through government programs like Medicare
or through surveys of doctors themselves.
D. Do Doctors Need the Privilege of Unrestricted Off-Label Prescribing to
Provide Quality Patient Care?
Off-label prescribing has strong supporters among lawyers representing the
pharmaceutical industry who often frame their articles as being on behalf of
patients because the practice allows physicians to provide care consistent with
their professional judgment.175
172. JENNIFER KAO, PHARMACEUTICAL REGULATION AND OFF-LABEL USES 2 (2016),
http://www.nber.org/aging/valmed/WhitePaperKao2_2017.pdf (reviewing “empirical evidence on
pharmaceutical regulation and private investments from the health economics and health policy
literature regarding off-label use”); see also Randall S. Stafford, Regulating Off-Label Drug Use—
Rethinking the Role of the FDA, 358 NEW ENG. J. MED. 1427, 1429 (2008), (discussing limits on
the FDA and relaxation of oversight as well as the drug industry’s exploitation of areas of
ambiguity).
173. See Jerry Vorn Darrow, Jerry Avorn & Aaron S. Kesselheim, FDA Approval and
Regulation of Pharmaceuticals 1983−2018, 323 J. AM. MED. ASS’N 164, 173 (2020).
174. See Francis Lamontagne et al., A Living WHO Guideline on Drugs to Prevent Covid-19,
372 BMJ 1, 2, 4 (2021), https://www.bmj.com/content/372/bmj.n526 (the World Health
Organization issued a “Living Directive” that “recommend[ed] against the use of
hydroxychloroquine as prophylaxis in individuals who do not have covid-19 (strong
recommendation; high certainty evidence)”).
175. James M. Beck & Elizabeth D. Azari, Off-Label Use, and Informed Consent: Debunking
Myths and Misconceptions, 53 FOOD & DRUG L.J. 71, 76−80 (1998); Rodney A. Smolla, OffLabel Drug Advertising and the First Amendment, 50 WAKE FOREST L. REV. 81, 87 (2015) (“Why
do doctors so often prescribe medications for off-label uses? It cannot be that doctors do not know
what they are doing, do not care for their patients, or have somehow been seduced or suckered by
drug companies. . . . The most plausible intuitive answer . . . is that doctors prescribe medications
for off-label uses because they have made the independent, professional medical judgment that the
prescription, on balance, holds more promise of doing good for the patient than harm.”).
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But this is not necessarily how doctors themselves view it. A recent survey
of board-certified internists found among 600 respondents that “60% of
respondents felt that the FDA should ‘definitely not’ or ‘probably not’ allow offlabel directly to physicians” with an even greater number endorsing the
statement that “it would be a ‘bad idea’ or ‘terrible idea’ to allow off-label
promotion in doctors’ offices (71%) or in medical journals (68%).”176 Their
disapproval of the practice was based on concern that it may “increase
prescriptions for drugs without meaningful benefits (61%; n = 416) and for
diseases not previously considered medical problems (84%; n = 568)”; few saw
off-label promotion as helpful with “[o]nly 30% of respondents” agreeing “that
off-label promotion could improve clinical decisions.”177 Slightly under half of
those surveyed (42%) endorsed an even stronger statement that “off-label
promotion might actually worsen clinical decisions.”178 But their criticism of
the FDA, for being too lax on off-label promotion, did not translate into a call to
restrict the ability of individual physicians to prescribe off-label.179
Moreover, arguments against restricting off-label prescribing start from the
false premise that it would be an exception to the unfettered freedom that
physicians already enjoy. If this was ever true, it is not reflective of today’s
health care environment. Because the most expensive feature of the U.S.
Healthcare System is the unrestrained cost of pharmaceuticals, biologics, and
medical devices,180 managing the cost of medications is a high priority for
hospitals and public and private healthcare funders. Since Medicare does not
cover out-of-hospital prescriptions, enrollees are encouraged to purchase
additional prescription drug insurance from private companies which have their
own formularies.181 Whether it is imposed by managed care or hospital
administrators, almost no doctors in the United States prescribe outside the
parameters of a drug formulary.182
176. Gayle Denney, Majority of Doctors Think the FDA is Doing this Wrong, MDLINX (May
8, 2020), https://www.mdlinx.com/article/majority-of-doctors-think-the-fda-is-doing-this-wrong/
1F436iHEpIensIfjPNOytk (citing Jerry Vorn Darrow & Aaron S. Kesselheim, FDA Approval and
Regulation of Pharmaceuticals, 323 J. AM. MED. ASS’N 164 (2020)).
177. Id.
178. Id.
179. Id.
180. Because the U.S. does not have a single-payer system, and has even legally prevented
those running the systems for which the government does pay for like Medicare, Medicaid, and the
Veteran’s Administration from bargaining for prices. In some respects, we have allowed an ad hoc
form of regulation by cost in which a doctor can prescribe anything, but a patient can only be
reimbursed for a limited formulary.
181. What Is a Prescription Drug Plan Formulary, MEDICARE.COM (last updated Sept. 15,
2018), https://medicare.com/medicare-part-d/what-is-a-prescription-drug-plan-formulary.
182. The Petrie-Flom Center Staff, Massachusetts Wants To Drive Down Medicaid Drug
Costs: Why Is The Administration So Nervous?, HARV. L.: BILL OF HEALTH (Apr. 6, 2018),
https://blog.petrieflom.law.harvard.edu/2018/04/06/massachusetts-wants-to-drive-downmedicaid-drug-costs-why-is-the-administration-so-nervous/ (“Although drug formularies are
ubiquitous in Medicare and the private insurance market, they’re absent in Medicaid.”); Formulary
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Suggestions that regulating off-label prescribing would create an undue
burden on health care provers also ignores the reality that both state and federal
law restrict the prescribing of drugs that the federal government has identified
as having potential to be abused outside of the healthcare setting.183 The
growing concern about deaths associated with opioid use has led to legislatures
limiting provider prescribing authority to pursue societal public health goals.
The result is that all 50 states and territories have now adopted some form of
prescription drug monitoring programs (PDMP) to track individuals who are
prescribed opioids by more than one provider.184 As scheduled drugs, both the
federal government and state governments have overlapping authority to impose
limitations on both opioids intended to treat pain and opioid formulations
intended to treat addiction.185 Without endorsing the effectiveness of these
programs or minimizing the horrifying and, perhaps, unintended consequences
they have had on limiting access to opioids by those who need them the most, it
is impossible to ignore the reality of their existence.
Finally, restrictions on off-label prescribing are often described as
unwarranted criticisms of physicians themselves.186 So much so that a 2011
article advocating “binding legal regulation” of physician’s powers to prescribe
off-label predicted that their argument “is new and will be controversial”
because “society has a strong tradition of deference to physicians’ autonomy and
judgment in the context of the physician-patient relationship.”187 As a result of
this deference, not only has “off label” prescribing “never been effectively
Management, AMCP (July 18, 2019), https://www.amcp.org/about/managed-care-pharmacy101/concepts-managed-care-pharmacy/formulary-management (“Formulary management systems
are routinely used by health plans, pharmacy benefit management companies (PBMs), hospitals
and government agencies, including the Veterans Health Administration, Department of Defense,
and Medicare and Medicaid programs.”).
183. See Controlled Substances Act, Pub. L. No. 91-513, 84 Stat. 1242 (1970) (codified as
amended at 21 U.S.C. §§ 801−971 (2018)).
184. Joanne E. Brady et al., Prescription Drug Monitoring and Dispensing of Prescription
Opioids, 129 PUBLIC HEALTH REP. 139, 140 (2014).
185. Following the much publicized death of Michael Jackson after being treated by his
personal physician with Profonal, an aesthetic that can only be safely used in a hospital; the Drug
Enforcement Agency considered adding it to the list of scheduled substances and restricting its use
outside of hospitals. However, that did not happen.
Propofol, DEA (2020),
https://www.deadiversion.usdoj.gov/drug_chem_info/propofol.pdf; DEA Weighs Limits for Drug
in Jackson Case, CBS NEWS (July 15, 2009, 5:32 PM), https://www.cbsnews.com/news/deaweighs-limits-for-drug-in-jackson-case/; DEA might tighten restrictions on sedative propofol,
CNN (July 16, 2009), http://edition.cnn.com/2009/HEALTH/07/15/propofol.dea.jackson/index.
html.
186. Sandra H. Johnson, Polluting Medical Judgement? False Assumptions in the Pursuit of
False Claims Regarding Off-Label Prescribing, 9 MINN. J.L. SCI. & TECH. 61, 64, 73 (2007) (citing
Troyen A. Brennan et al., A Social Science Perspective on Gifts to Physicians From Industry, 290
J. AM. MED. ASS’N 252, 252−53 (2003); Ashley Wazana, Physicians and the Pharmaceutical
Industry: Is a Gift Ever Just a Gift?, 283 J. AM. MED. ASS’N 373, 373 (2000)).
187. Phillip M. Rosoff & Dorianne Lambelet Coleman, The Case for Legal Regulation of
Physicians’ Off-Label Prescribing, 86 NOTRE DAME L. REV. 649, 659 (2011).
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regulated, [t]o the contrary . . . even discussing such regulation is taboo.”188 In
2008, rejecting a then common view that off-label prescribing was due to
financial incentives provided by pharmaceutical companies,189 Sandra Johnson
argues that “the prevalence of off-label prescribing” is not a result of low level
bribery so much as it “is a manifestation both of learning patterns in the medical
profession and deficiencies in the production and dissemination of clinical
knowledge” which prioritizes information from other physicians more than
medical journal articles.190
These arguments that restricting off-label prescribing are actual expressions
of distrust, find some traction in an environment where medical training and
practice leave physicians feeling unappreciated and burnt out.191 The process of
becoming a doctor in the United States is not just challenging, it is expensive
and often brutal. With medical tuitions at some schools in excess of $100,000,
doctors often graduate hundreds of thousands of dollars in debt only to find
themselves locked into another three years of training at what seems, to them,
the absurdly low salary of $60,000, on average.192 As one popular commentator
on the experience of new physicians explains,
188. Philip M. Rosoff & Doriane Lambelet Coleman, The Case for Legal Regulation of
Physicians’ Off-Label Prescribing, 86 NOTRE DAME L. REV. 649, 659 (2010); William
L. Christopher, Off-Label Drug Prescription: Filling the Regulatory Vacuum, 48 FOOD & DRUG
L.J. 247, 247 (1993) (noting that “physicians attack some attempts to regulate medicine with the
vigor of an artist resisting censorship” and that “[t]he medical community argues that
overregulation chills innovation and reduces medicine to ‘cookbook’ therapy”).
189. Most health insurance programs cover the cost of drugs prescribed off-label. For an
example of the policy of a private company, see Off-Label/Unproven Specialty Drug Treatment,
UNITED HEALTHCARE (effective Aug. 1, 2021), https://www.uhcprovider.com/content/dam/
provider/docs/public/policies/comm-medical-drug/off-label-unproven-specialty-drugtreatment.pdf.
190. Sandra H. Johnson, Polluting Medical Judgement? False Assumptions in the Pursuit of
False Claims Regarding Off-Label Prescribing, 9 MINN. J. L. SCI. & TECH. 61, 64 (2008). Her
claim is that the training practicing physicians receive inculcates a “universal skepticism . . .
regarding the utility of scientific literature” in contrast to “clinical experience.” Id. at 74−75.
Therefore, they are more likely “to rely on opinions of respected peers and opinion leaders within
the profession rather than on clinical studies or clinical guidelines standing alone.” Id. at 76. She
also notes that negligence standards that emphasize following “standards of care” promote reliance
on seeking “safety in the herd.” Id. at 81.
191. See generally Sharona Hoffman, Healing the Healers: Legal Remedies for Physician
Burnout, 17 YALE J. HEALTH, POL’Y, & ETHICS 56, 67 (2019) (noting high levels of physician
burnout in the U.S. “characterized by emotional exhaustion, negativity, cynicism, and a sense of
lack of accomplishment and job fulfillment”).
192. Keith L. Martin, Medscape Residents Salary & Debt Report 2019, (July 17, 2019),
https://www.medscape.com/slideshow/2019-residents-salary-debt-report-6011735. It is important
to note that while this vast amount of debt would be intimidating to anyone, it reflects a reality in
which every graduate of an American medical school can expect to obtain a residency and after
completion, a job that, on average, pays $200,000 in the first year. As one blogger explains,
“despite the many unique issues physicians have to deal with, there is no reason for them not to be
rich, eventually.” Why Aren’t Doctors Rich?, THE WHITE COAT INVESTOR, https://www.whitecoat
investor.com/personal-finance/why-arent-doctors-rich/ (last visited July 26, 2020).
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“Physicians have struggled and sacrificed to develop the clinical
judgment and skill needed to provide competent clinical care. They
have undergone over a decade of schooling and training, taken on
excessive student loan debt, worked backbreaking hours for low pay
during residency, and risked their lives during the process. Yet when
they have completed their training, they often times have to pay
excessive malpractice premiums, having to answer to bureaucrats,
administrators, insurance companies, politicians, and lawyers.”193
The price of being a doctor has become even higher with the coming of
COVID-19. As physician, poet, and author Dr. Colleen Farrell wrote recently
in The Nation, the experience of doctors caring for patients with COVID-19 is
analogous to those who watched their patients die of AIDS in the 1980s. Like
them, she believes that she and her peers will be permanently marked by what
they experienced. She writes:
“Some of my colleagues describe what we have seen as war. Others
call it a mass casualty event. I am still struggling to find the words to
name it. But whatever we call it, I do not want to rush to heal from it.
I need time to sit in the darkness and tend to the sorrow.”194
E. Do Patients Need Off-Label Prescriptions?
Turning from doctors to patients, some argue that off-label prescribing is
necessary because of the inherent slowness of the current drug approval
process.195 As a result, patients are harmed because they cannot get access to

193. Christopher H. Loo, How COVID-19 is Forcing Physicians to Rethink the Concept of Job
Security, KEVINMD.COM (May 5, 2020), https://www.kevinmd.com/blog/2020/05/how-covid-19is-forcing-physicians-to-rethink-the-concept-of-job-security.html.
194. Colleen M. Farrell, Witnessing the Pandemic From the Front Lines at New York City’s
Oldest Public Hospital, THE NATION (July 13, 2020), https://www.thenation.com/article/society/
bellevue-mourning-inequality-coronavirus/.
195. Sandra H. Johnson, Polluting Medical Judgment? False Assumptions in the Pursuit of
False Claims Regarding Off-Label Prescribing, 9 MINN. L.J. SCI. & TECH. 61, 64 (2008) (arguing
that the prevalence of off-label prescribing is not merely because of drug company efforts to
increase profits but rather reflects “deficiencies in the production and dissemination of clinical
knowledge”). “There were multiple barriers to clozapine access including prescriber-related
barriers: lack of personal prescribing experience, concerns about clozapine blood monitoring and
adverse effects; and institutional issues such as prescribers’ adherence to evidence-based medicine
principles and a local ‘culture’ of clozapine prescription.” Hélène Verdoux et al., Prescriber and
Institutional Barriers and Facilitators of Clozapine Use: A Systematic Review, 201
SCHIZOPHRENIA RSCH. 10, 17 (2018) (finding that the relevant factor in willingness of physicians
to prescribe one anti-psychotic drug over another wasn’t information but rather the prescribing
practices of other physicians in their geographic area); see David C. Radley et al., Off-label
Prescribing Among Office-Based Physicians, 166 ARCH. INTERN MED. 1021, 1021 (2006) (“Offlabel medication use is common in outpatient care, and most occurs without scientific support.
Efforts should be made to scrutinize under evaluated off-label prescribing that compromises patient
safety or represents wasteful medication use.”); see also Monika K. Kryzanowska, Off-Label Use
of Cancer Drugs: A Benchmark is Established, 31 J. CLINICAL ONCOLOGY 1125 (2013).
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drugs they need.196 The present issue remains that the current system
incorporates no mechanisms for getting data of off-label prescribing practices
back to the FDA in a form that might allow it to evaluate them for safety and
efficacy. If a drug sponsor, physician, or anyone else has a good faith belief that
an approved drug might be helpful in treating a condition other than that for
which it was approved, the action most helpful to patients is to start a clinical
trial.197 So, for example, if hydroxychloroquine is already safe and effective for
the population of people living with Lupus, then a clinical trial will show
whether it is safe and effective for people infected with COVID-19. Also,
developments in precision medicine have made it possible to assess treatments
for safety and efficacy in so that it is no longer necessary to engage in guess
work.198 This reflects a reality that not all patients respond in the same way to
the same treatment.199
The field of precision medicine is in its early days with advances being made
quickly. It is increasingly popular to see patterns that were not apparent when
studies were originally conducted. But if sponsors were required to generate
information about the genetic profile of the patients in their studies, it would
build a foundation on which to build later research that may extend uses.
IV. HOW OFF-LABEL PRESCRIBING BECAME ENTANGLED WITH FIRST
AMENDMENT CLAIMS
Claims that pharmaceutical companies had protected first amendment rights
to promote their products started to increase in frequency from the moment that
the FDA first issued guidance suggesting that it would be illegal for
pharmaceutical companies to promote off-label use of their products to
physicians who could write legal prescriptions.200
196. Sandeep Kumar Gupta & Roopa Prasad Nayak, Off-Label Use of Medicine: Perspective
of Physicians, Patients, Pharmaceutical Companies and Regulatory Authorities, 5 J.
PHARMACOLOGY & PHARMACOTHERAPEUTICS 88, 92 (2014).
197. Andre C. Kalil, Treating COVID-19—Off-Label Drug Use, Compassionate Use, and
Randomized Clinical Trials During Pandemics, 323 J. AM. MED. ASS’N 1897, 1898 (2020) (“It is
imperative to discover new therapies, otherwise there will be no proven treatments for future
coronavirus pandemics. By participating in an RCT, both patients and clinicians can benefit from
the unique opportunity to directly contribute to the discovery of new therapies, and also from the
safer monitoring process in the conduct of clinical trials compared with uncontrolled drug
administration (whereby safety cannot be determined).”).
198. A. Han et al., The Promise of Big Data for Precision Population Health Management in
the US, 195 PUB. HEALTH 110 (2020).
199. The Promise of Precision Medicine, NAT’L INST. OF HEALTH (last reviewed Feb. 12,
2020), https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/promise-pre
cision-medicine.
200. John E. Osborn, Can I Tell You the Truth? A Comparative Perspective on Regulating OffLabel Scientific and Medical Information, 10 YALE J. HEALTH POL’Y L. & ETHICS 299, 303 (2010)
(“If the history of Western civilization may be seen as one long battle pitting order against freedom,
the government’s effort to curtail off-label speech might be dismissed as a minor skirmish on the
outskirts of town. However, this issue is anything but minor in policy terms.”).
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A. Pharmaceutical Advertising as Commercial Speech
In a series of cases starting with Pharmacy Board v. Virginia Citizens
Consumer Council in 1976,201 the United States Supreme Court developed the
principle that while advertising had not previously been protected under the First
Amendment, it should be in order to maintain a “free flow of commercial
information” so that consumers could make informed choices.202 Under this
theory which the Court has supported and continues to develop, both those
making statements to market their products and consumers who might use that
information to make purchasing decisions had a right to be protected against
government restrictions.203 Under what is now called the “Commercial Speech
Doctrine,”204 the government could only regulate truthful marketing of a legal
product if it had a “substantial” interest that would be advanced “directly” by
the restriction.205
In 2011, the United States Supreme Court in Sorrell v. IMS struck down a law
restricting pharmaceutical manufacturers’ access to the prescribing practices of
individual doctors for the purpose of developing marketing strategies targeting
doctors because it limited their ability to promote their products and therefore
from exercising their right to free speech as protected by the Free Speech Clause
of the First Amendment.206 Seven years later, in 2018, the Second Circuit Court
of Appeals in United States v. Caronia, cited Sorrell when vacating the criminal
conviction of a pharmaceutical sales person who was found to have been
discussing the off-label use of a drug with doctors who had the power to
prescribe it.207 The challenge to the Vermont law had been mounted by a
coalition of business interests led by the Washington Legal Foundation (WLF),
who brought suit in federal court claiming that the FDA guidance overstepped
its congressional authority. Commenting on their victory, WLF characterized
201. Virginia State Bd. of Pharmacy v. Virginia Citizens Consumer Council, Inc., 425 U.S.
748 (1976).
202. Id. at 764−65.
203. Id. at 756 (“Freedom of speech presupposes a willing speaker. But where a speaker exists,
as is the case here, the protection afforded is to the communication, to its source and to its recipients
both. This is clear from the decided cases.”).
204. For an overview of the development of the commercial speech doctrine, see David
Schultz, Commercial Speech, FIRST AMEND. ENCYCLOPEDIA (2009), https://mtsu.edu/first-amend
ment/article/900/commercial-speech.
205. Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n of New York, 447 U.S. 557, 564
(1980).
206. Sorrell v. IMS Health Inc., 564 U.S. 552, 557 (2011) (“Speech in aid of pharmaceutical
marketing . . . is a form of expression protected by the Free Speech Clause of the First
Amendment.”).
207. United States v. Caronia, 703 F.3d 149, 163 (2d Cir. 2012); see also Lars Noah, Banning
Off-Label Drug Promotion Offends the U.S. Constitution: Making the Strongest Case, 83 ALB. L.
REV. 301 (2020) (applying the holdings of Sorrell and Caronia to explain why restrictions “on
promoting off-label uses to bar generic drug manufacturers from touting uses newly approved by
the FDA but only for their brand-name competitors cannot possibly pass muster under the First
Amendment.”).
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the decision as a victory for patients because “[b]y prosecuting those engaged in
truthful speech about off-label uses of medical products, the federal government
has significantly hindered health care delivery in this country.”208 Michael
Carvin, the attorney representing WLF, opined that “[o]ff-label use is essential
to good medical practice because the medical community’s knowledge of the
drug effectiveness inevitably outpaces the painstaking FDA approval process for
label changes. In many circumstances off-label use is standard-of-care
medicine.”209 U.S. v. Caronia never produced a binding precedent beyond the
Second Circuit because after losing, the FDA backed away and withdrew the
offending guidance.210
Since then, the continuing movement to protect and promote off-label
prescribing had become a proxy for a movement seeking to extend the
constitutional protection for commercial speech even as the practice of off-label
prescribing continued to be under critical review even before the president’s
advocacy for hydroxychloroquine.211
B. Pharmaceutical Companies Use of Social Media as a Venue for Promoting
Off-Label Prescribing
Some suggest that one of the reasons pharmaceutical companies began
funding disease-focused patient groups was to create opportunities for
information about off-label use to spread among a community highly motivated
to find information about their own industry.212 Whatever pharmaceutical
companies were able to accomplish through patient groups and physicians
willing to be unpaid spokesmen, though, is a tiny fraction of what has become
available in health and wellness communities of social media.
On January 15, 2020, an organization impressively named “the Association
of American Physicians and Surgeons”213 and a group of individual plaintiffs

208. Thomas Sullivan, United States v. Caronia: A Victory for Free Speech vs. Off Label
Promotion, POL’Y & MED. (May 6, 2018) https://www.policymed.com/2012/12/united-states-vcaronia-a-victory-for-free-speech-vs-off-label-promotion.html.
209. Id. For a recent overview of the issue, see Noah, supra note 207.
210. See Noah, supra note 207.
211. Joan H. Krause, Truth, Falsity, and Fraud: Off-Label Drug Settlements and the Future of
the Civil False Claims Act, 71 FOOD & DRUG L.J. 401, 402−03 (2016) (“While the pharmaceutical
industry may be losing the battle of public opinion, it is winning important victories in the war over
First Amendment commercial speech protection.”).
212. Laura Karas et al., Pharmaceutical Industry Funding to Patient-Advocacy Organizations:
A Cross-National Comparison of Disclosure Codes and Regulation, 42 HASTINGS INT’L & COMP.
L. REV. 453, 454 (2019), https://repository.uchastings.edu/cgi/viewcontent.cgi?article=1836&
context=hastings_international_comparative_law_review.
213. About AAPS, ASS’N OF AM. PHYSICIANS & SURGEONS, https://aapsonline.org/aboutaaps/. Founded in 1943 the organization describes itself as “a non-partisan professional association
of physicians in all types of practices and specialties across the country.” It describes its main role
as fighting to “[p]reserve [m]edical [f]reedom” and help “[p]hysicians [r]educe and [e]liminate
[t]hird [p]arty [i]nterference.”
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filed suit against Congressman Adam Schiff claiming that his efforts to get social
media companies to stop spreading false information about COVID-19
treatment and vaccines was unconstitutional censorship.214 They did so on the
grounds that a letter he, a public official, sent to a private company, Facebook,
had the effect of depriving the right of individuals “who seek access to vaccine
information” to such information in violation of the First Amendment to the U.S.
Constitution.215 AAPS’s lawsuit comes in the context of a vigorous public
debate about the role of private companies that create websites where people can
come together and talk about topics of mutual interest. Pharmaceutical
companies may also be working directly with patients through their funding of
what are usually called patient “advocacy groups.” As Emily Kopp explained,
“[t]he ‘patient’ voice is speaking with a pharma accent.”216 Despite numerous
calls for regulation, and the example of such regulations from overseas, there is
so far no obligation for any organization to report the extent of its support from
pharmaceutical companies beyond the minimum required to maintain their taxexempt status.217
CONCLUSION
President Trump’s personal advocacy on Twitter and in public statements for
the use of hydroxychloroquine to combat COVID-19 has had a destructive
impact well beyond his term in office. While it may still be years before social
scientists have fully identified the impact of his advocacy, the immediate rise in
prescriptions has been thoroughly documented. But this initial impact which
created shortages for those who depended on it to combat auto-immune disease
was only the beginning of a cascade of negative consequences which included
first subjecting people to the risks of taking a powerful drug of no benefit to
them and then more broadly supporting a culture of rejecting FDA as a source
of credible information. Again, only time will fully explore the extent to which
this belief in the preventive and curative powers of hydroxychloroquine and
ivermectin caused people to reject vaccines and effective treatments, early

214. Complaint at 4, Ass’n of Am. Physicians & Surgeons v. Schiff, No. CV 20-106 (RC),
2021 WL 354174 (D.D.C. Feb. 2, 2021), https://aapsonline.org/judicial/aaps-v-schiff-1-152020.pdf.
215. Ass’n of Am. Physicians & Surgeons, Rep. Adam Schiff Sued by Physicians for Censoring
Vaccine Debate (Jan. 15, 2020), https://aapsonline.org/rep-adam-schiff-sued-by-physicians-forcensoring-vaccine-debate/.
216. Emily Kopp, Patient Advocacy Groups Rake In Donations From Pharma, KAISER
HEALTH NEWS (Mar. 1, 2017), https://khn.org/news/patient-advocacy-groups-rake-in-donationsfrom-pharma/; McCoy, supra note 164, at 882; see also Susannah L. Rose et al., Patient, Advocacy
Organizations, Industry Funding, and Conflicts of Interest, 177 J. AM. MED. ASS’N INTERNAL
MED. 344, 348 (2017) (finding that 67% reported receiving industry funding as 11.9% “received
more than half of their revenue from for-profit companies”).
217. Susan Thaul, CONG. RSCH. SERV., R45792, OFF-LABEL USE OF PRESCRIPTION DRUGS 1
(2021).
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evidence shows that many claim to have done so based on the President’s
statements even though he never explicitly advocated that they do so.
What is important for lawyers and policy makers today, though, is to look
closely at the legislative structure that allowed the President’s tweets about
hydroxychloroquine and the social media advocates of ivermectin. The very
public resulting rush to prescribe both of these drugs long after they had been
definitively found to be ineffective provides an opportunity to re-consider
unrestricted off-label prescribing. This article has not called for abolishing
either off-label prescribing or even very broad prescribing privileges, but to
evaluate their role in a world where healthcare is delivered very differently than
it was during the 1950s when the FDA was given power to approve drugs. It
has been more than ten years since Congress gave any serious consideration to
off-label prescribing.
First, as an initial measure to promote fairness and transparency, prescribers
could be obligated to inform patients that they are being prescribed a drug that
has not been approved by the FDA for this particular use.218 Second, rather than
simply fight off-label prescribing by criminally investigating pharmaceutical
companies who seem to be promoting its use, it would be more productive to
create a pathway for off-label use by creating a streamlined process for the
review of data supporting new uses of an already approved product.219 As I have
proposed in an earlier article regarding the reporting of post-approval adverse
events, the cost of any registry system should be borne by the company
sponsoring the drug since they are the ones who benefit financially when their
drugs are prescribed off-label.220

218. Id. at 9 (“Congress could require or work with the states to require that the prescriber
inform the patient about the off-label use and describe the meaning of off-label use; the prescriber
note in the prescription why the drug is being prescribed; or the pharmacist inform the patient that
the use is off-label”).
219. Id. at 9–10.
Congress and other public policy groups consider whether and how to address off-label
drug prescribing, they do not have adequate information on the scope and details of the
practice. Congress could require or work with the states to encourage clinicians to note
on prescriptions the reason for medication use (e.g., the specific condition, disease, or
symptom), thereby allowing that information to appear in pharmacy databases, which
would enable focused analysis of off-label uses; the establishment of confidential
registries of off-label prescribing and follow-up information that FDA (or other
designated scientifically appropriate agencies) could use in its electronic surveillance
systems to identify associated adverse events and other drug use problems; or FDA to
increase its surveillance of available data sources, such as registries and administrative
and clinical databases, to identify patterns of off-label use and evidence suggesting
effectiveness and associated adverse events.
220. Jennifer S. Bard, Putting Patients First: How the FDA Could Use Its Existing Powers to
Reduce Post-Market Adverse Events, 10 IND. HEALTH L. REV. 495, 528 (2013) (“The central
premise of this article is that the FDA should be using all its powers to develop systems intended
to reduce the harm suffered by patients from problems that only emerge after a product is on the
market. But within the reality of the FDA’s funding base, it suggests that among these powers is
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No one doubts the commitment of health care providers to their patients or
their bravery. Nor should we ignore the administrative burdens all practicing
healthcare workers face from a fragmented healthcare system and the stress they
feel, whether warranted or not, from the threat of malpractice suits. But the
existence of one bad system does not justify the existence of another. We should
use this opportunity to identify and address the prescribing practices that have
evolved to place, in general, no boundaries on physician prescribing and, in
specific, a frequently used backdoor that allows drugs to be used without FDA
review for safety and efficacy.

the ability to shift the cost for these systems to those who stand to benefit financially from the
product’s success: its sponsor.”).

